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ABSTRACT
An Analysis of Situated Meaning in Direet-To-Consnmer 
Pharmaeentieal Advertising
by
Susan E. Garcia
Dr. Denise Tillery, Examination Committee Chair 
Associate Professor o f English 
University of Nevada, Las Vegas
This thesis uses interpretive discourse analysis to critically examine the situated 
meaning o f prescription drug Direct-To-Consumer Advertising (DTCA) as compared to 
the situated meaning o f historical patent DTCA. Specifically, I apply James Paul Gee’s 
theory o f analysis to show how the DTCA, past and present, builds identity, connections, 
and sign systems and knowledge. My analysis demonstrates that the coverage and 
convergence o f these building tasks in both prescription and patent DTCA indicate that 
today’s pharmaceutical companies’ situated meaning is not significantly different from 
the patent medicine advertising o f the past. Despite pharmaceutical companies’ claims 
that the prescription DTCA educates consumers, the discourse does not substantiate a 
situated meaning beyond that o f a manufacturer selling a product. Understanding the 
motivation and language of pharmaceutical advertising will enable us, as consumers and 
patients, to make sound decisions about the medications we endorse.
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CHAPTER 1 
INTRODUCTION
Consumers are bombarded on a daily basis with advertisements in television 
commercials and the printed pages o f popular magazines. As one o f the highest grossing 
products sold today, prescription drugs are featured in Direct-To-Consumer Advertising 
(DTCA) and have taken their place among ads which offer consumers a choice in what 
they purchase. The dilemma of DTCA for the medical profession, however, lies in the 
fact that the consumer cannot simply go out and buy the advertised drugs as they would 
any other item featured in an ad -  a physician must be involved in the process. As a 
result, the medical profession finds itself not only prescribing proper treatments for 
patients, but also dissuading patients’ desires for advertised drugs which are not 
medically indicated.
This situation is not completely new, and the discourse of DTCA has long been a 
complex factor in a patient’s decision between appropriate and inappropriate healthcare 
choices. In fact, opposing viewpoints -  typically physicians against pharmaceutical 
companies -  about the discursive nature of DTCA complicate a patient’s decision 
because opponents of the practice contend it is merely a slick marketing tool which has 
not changed since patent medicine days while proponents of DTCA argue that the 
practice is more than simply a product-sales technique and has a much more valuable
intent. As consumers, then, we are left to mediate between the two sides, so we must be 
aware o f the authorial intention behind pharmaceutical advertising in order to make 
sound healthcare decisions. To that end, using qualitative discourse analysis, this thesis 
examines a corpus o f both historical and modem pharmaceutical print advertising to 
discover the similarities or differences in situated meaning evident in the persistent 
methods o f medicine marketing. Since pharmaceutical advertising is such a large field 
for analysis, this study limits its selection o f artifacts to two major patent medicines -  
Lydia Pinkham’s Vegetable Compound and Peruna -  from the past and two hugely 
popular prescription medications -  Nexium and Lipitor -  featured in print media today. 
This first chapter will establish the background for the study and provide an overview of 
the literature already available on DTCA of past and present, while foregrounding 
society’s vested interest in the tactics o f medicine promotion.
Background to this DTCA Study
A short review o f medication and drug advertising reform as it developed within FDA 
regulation is necessary because it provides a historical and sociological context for 
looking at the various ways in which medicines were introduced to the public. The topic 
o f pharmaceutical advertising is closely tied to events in the development and sale of 
drugs and strongly influences society’s views of these medicines.
Although not officially given the term Direct-To-Consumer Advertising in the 
centuries before Food and Drug Administration (FDA) regulation was established, the 
medicines offered to the public in earlier centuries via handbills and advertising media set 
the precedent for today’s frequently critiqued marketing techniques. In the past.
however, drawing a definitive line between benefieial medieines and fake, or quaek, 
nostrums was diffieult beeause the recuperative, physieian-sanctioned remedies were 
very rarely diseussed or highlighted in the media. Instead, patent medieines were those 
drugs frequently advertised to the publie and, by definition, were those seeret reeipes that 
originally won the blessing of the royalty in seventeenth- and eighteenth-eentury 
England. In the late eighteenth-, nineteenth- and early twentieth-century America, patent 
medieines were not offieially “patented,” but the ingredients still remained the sole 
knowledge o f the maker. These patent drugs could be, and often were, a eomposite o f 
many ineffective or dangerous ehemieals.
On the other hand, proprietary medieines were usually those drugs whieh physieians 
and pharmacists devised, but whose primary ingredients were available to those who 
needed to know a drug’s content. Most often, doetors would write a preseription for a 
medieine with the full eomprehension of all ingredients. It was also not unusual for 
pharmaeists to write and provide prescriptions for patients, too. Proprietary medicines, 
then, were often seen as being more ethical than the questionable patent drugs. As a 
result, doetors eould simply recommend that patients avoid any medieines whieh were 
openly marketed to the public because the products were patent, or quaek, drugs. For 
decades the unadvertised proprietary medieations were the only doctor-reeommended 
alternatives to patent drugs.
Whatever moral difference that could be said to exist between patent and proprietary 
drugs, however, disappeared when the makers o f both types of medieine began to 
advertise to the general public. Once the layman beeame the target for advertising 
appeals o f any drug manufaeturer, physieians and eritics denouneed the promoted
medicine as being fraudulent. The Proprietary Association o f America (PAA) tried to 
defend its members’ products from being labeled as “quackery,” but they often found 
themselves labeled the “patent medicine ‘combine’” (Adams 45) because critics often 
saw the PAA as being part o f a larger entity which sold any drug to the public with little 
concern for consumer safety. At the same time, patent medicine makers fought for their 
products by claiming any restriction on advertising was a loss o f freedom for the public 
(Carson 32). Once the distinction between valuable remedy and fake cure became 
dangerously blurred, the FDA stepped in with strong measures intended to protect the 
consumer in 1906.
Today, we face another patent/proprietary pharmaceutical industry that fosters a 
proliferation o f DTCA, with many large companies spending several billion dollars per 
year in advertising costs. Most pharmaceutical companies patent at least a few key 
ingredients in their new prescription drugs and strive to gain brand name loyalty before 
the patent expires. This desire to build a strong consumer base for their medicines 
necessitates very competitive strategies on the part o f the drug makers. With FDA 
regulations governing their products and advertising, these companies offer legitimate 
medicines and cannot usually be accused o f quackery as patent medicine makers were 
prior to FDA laws. Still, the present debate about specific advertising appeals and 
situated meaning o f today’s DTCA discourse hearkens back to a time when drug 
advertising to the public was considered highly inappropriate. Moreover, doctors today 
can no longer use the issue of advertising as the sole argument to convince a patient of a 
drug’s contraindication for a specific health condition.
DTCA prior to any FDA regulations that changed restrictions on prescription drug
advertising is easily plaeed along signifieant points on a timeline (see Figure 1). The 
period before 1905 is a time when patent medicines were advertised to the public with 
virtually no restriction by the government. The years between 1905 and 1962 are clearly 
defined as important turning points in the control o f patent medicine and all 
pharmaeentieal advertising. Finally, the span between 1962 and 1980 is a time when 
pharmaceutical companies marketed prescription drugs solely to physieians.
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Figure 1. Timeline for Regulation o f Drugs and DTCA
In 1906, the FDA acted on critical demand for federal intervention by first passing the 
Pure Food and Drug Act and then later transforming this regulation into the 1938 Federal 
Food, Drug, and Cosmetic Act. The 1906 Pure Food and Drug Act had only a limited 
impact on drug advertising beeause it centered most o f its attention on food. The 1906 
act did put restrictions on what could be printed on medicine labels, however, and 
exempted any drug in the United States Pharmacopoeia from the regulation (USC 59).
This action gave the advantage to the proprietary medicines that physicians most 
prescribed and thus limited the public’s access to names and messages typically featured 
as an early type of advertising on medicine bottles. Then, the 1938 Federal Food, Drug, 
and Cosmetic Act, also knows as the Wheeler-Lea Act, further expanded the control over 
patent medicines by limiting therapeutic claims, mandating adequate use directions on 
labeling, and granting prosecutorial power to the Federal Trade Commission (FTC) so it 
could take action against drug makers who advertised deceptively. The 1938 act also 
created a new category o f potentially dangerous drugs that had to have a prescription 
from a doctor (USC 75). Again, the FDA sent a message that drugs prescribed by a 
physician were safer and that the advertising tactics o f patent medicines were to be very 
limited in scope.
In 1951 and 1962, the FDA amended the Federal Food, Drug, and Cosmetic act in 
ways that wrested control o f pharmaceutical advertising from the FTC. The 1951 
amendment loosened some restrictions on less dangerous drugs, but maintained the 
requirement for a doctor’s prescription on “habit-forming” or toxic drugs (USC 82). As a 
result, the 1951 amendment also instituted strict guidelines for statements about the drugs 
to include any language used on the labeling o f medicine bottles or in public statements 
about the cautions and/or uses o f the drugs. As we have seen, FDA regulations through 
1951 touched on advertising tangentially, but, in 1962 the FDA finally made a point of 
specifically addressing drug advertising in an amendment that regulated the listing o f all 
ingredients on the label. This amendment also provided detailed requirements for 
aesthetics, such as the size and placement o f the font that had to appear in the
advertisements (USC 87). The FDA guidance did not specify any restrictions on the 
marketing appeals that can be used in the ads, however.
Review of Literature on Patent and Prescription Drug Advertising
Much o f the literature on contemporary prescription drug DTCA focuses on the 
historical context as well. Many books and articles detail the history o f prescription drug 
advertising, explaining that the practice did not really come into favor with the FDA until 
1980. Even then, the FDA was not convinced that prescription DTCA was a good idea, 
but many factors influenced the FDA to acquiesce to the pharmaceutical companies’ 
requests for broader marketing options. Alison Huang discusses, for example, the 
changing climate in terms of political and regulatory issues and the movement toward an 
emphasis on the patient’s empowerment in medical decisions as key motivating factors 
for prescription DTCA.
In addition to the historical information on the birth of pharmaceutical DTCA, 
existing literature establishes a context for the practice that demonstrates to readers why 
the rise o f prescription drug marketing to consumers has been so rapid since 1980. One 
reason often mentioned is that, since DTCA has created buy-in from the general public, 
physicians now feel they must comply with customer demand. In fact, studies show that 
“three quarters o f patients requesting drug prescriptions received them from their 
physicians” (Huang, 2240). Because the doctors are collaborating, in a sense, with the 
patients’ consumption o f prescription medications, pharmaceutical companies have 
enjoyed a very profitable cost/benefit ratio in regard to DTCA. Other miscellaneous 
factors also influence the increase in DTCA, such as new regulations on a physician’s
authority to prescribe specific drugs and the innovative ideas o f drug companies who find 
it less lucrative to sell their products only to doctors (Kravitz).
Rather than focus solely on the background for DTCA, other literature treats the 
prevalence of DTCA as an opportunity to detail the procedures that pharmaceutical 
companies should take to get their products into the DTCA arena. Devereux, for 
instance, shows drug manufacturers how to effectively implement product placement and 
devotes an entire chapter, “Will DTC work for your brand?” to the idea of brand name 
recognition for medicines. The pharmaceutical companies are encouraged to look at 
prescription drugs as being similar to any other commercial product, like a soft drink or a 
breakfast cereal. O f course, Devereux’s theory o f innovative drug promotion has raised 
some ethical questions about DTCA.
Furthermore, most texts written about DTCA for both patent and prescription drugs 
tend to focus on a couple o f major questions: 1) What are the ethical and legal issues of 
DTCA? and 2) Does DTCA change the doctor-patient relationship?
What are the ethical and legal issues o f  DTCA?
Discussions on the ethical problems o f medicine advertising inevitably invoke the 
name of Samuel Hopkins Adams and his series of articles written for Collier’s: The 
National Weekly. Adams, an outspoken journalist, is typically credited for motivating 
the federal government to move against patent drugs and to enact the Federal Food and 
Drug Act of 1906 (Carson; Helfand: Holbrook; Young). In his series, “The Great 
American Fraud,” Adams heavily criticizes both the patent medicine products and the 
practice of proprietary medicine advertising. The articles make no distinction between 
patent drugs and proprietary remedies, saying there was not enough difference between
the two to separate the “sheep” from the “goats” (Adams 3). To Adams, any drug maker 
who advertised publiely was an unethical participant in the delusion o f the public.
Adams explicitly spells out the major problems he saw with medicine advertising at 
the time and spares no opportunity to name speeifie examples o f patent medieine sellers 
who were defrauding soeiety. Particular targets of Adams’s critique were the numerous 
testimonials in the ads whieh greatly influeneed the seientifically “ignorant and gullible” 
minds of the publie (57) and the taeties, sueh as free samples and money-baek guarantees, 
which made repeat customers o f patients. As a proposed solution, Adams consistently 
calls for the federal government to make needed changes in the drug market; namely, to 
enforce the listing o f all ingredients on the drug’s label and to restrict the marketing of 
eertain drugs to a doctor for prescription because the doctor was in the best position to 
understand the drug’s eontents.
The American Medical Association (AMA) strongly agreed with Adams on the 
questionable ethies o f patent medieine advertising and included a speeial seetion in their 
report of 1908. In faet, the AMA was so coneemed about the suspect nature of 
patent/proprietary medicines that they formed a Council on Pharmacy and Chemistry to 
eonduet in-depth analyses of various drugs being offered to the eonsumer. In their 
findings, the AMA urged the federal government to plaee tighter eontrols on the use of 
paid testimonials in all periodieals. A particular target of criticism in the 1908 AMA 
report was the apparent abundanee of religious publieations that featured patent medieine 
advertisements. Interestingly, the AMA was not the first organization to quarrel with the 
religious papers who allowed pharmaeentieal advertising. Twenty years earlier in 1887, a 
report from the Texas Medieal Assoeiation published the same type of eritique stating.
“Go to the religious press and you will find it teeming with [medieine] advertisements” 
(101). Both the 1887 report and the 1908 AMA report take religious leaders to task with 
the remonstration that ethical preaehers did not advertise their services, so why should 
ethieal healtheare providers advertise?
Although accounts of patent medieines advertising do not always pass sueh negative 
judgment on the eharacter of the marketer, Stewart Holbrook makes the ease that many 
were outright criminals. In fact, Holbrook titled his book The Golden Age of Ouackerv 
because he sees the period before FDA regulation as a time when unscrupulous makers of 
drugs ran rampant in soeiety. Holbrook does provide insight, however, into the 
undeniable importanee of testimonials to non-regulated pharmaceutical advertising and 
forecasts a future in whieh testimonials will always play a vital role in medicine 
marketing.
James Harvey Young, whose book The Toadstool Millionaires: A Social Historv of 
Patent Medicines in America before Federal Regulation is often eited in diseussions on 
patent medieine (Carson; Porter; Stallings), is another author who explicitly details the 
successful use of testimonials in patent medicine advertising during the eighteenth and 
nineteenth centuries. In fact. Young’s book deseribes at length the great impact patent 
medicine had on soeiety in the years before the FDA began to regulate the praetice. Like 
Holbrook, Young believes that many doetors and apotheearies prepared proprietary 
drugs, but only the most unserupulous of people aetually advertised their drugs on the 
open market. Hence, these individuals were seen as frauds who needed to be controlled. 
Young does not analyze any drug advertisements of the early marketing period, but he 
does diseuss in general terms the marketing taeties o f quacks whieh “created the idea that
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doctors might be deceiving the patient if  they did not prescribe a medicine” (170). More 
importantly, Young alludes to an undesirable time in the future when even reputable 
medicine producers might be tempted to use the same advertising methods.
Literature that discusses the ethical and legal aspects o f prescription DTCA evinces 
distinctly opposite viewpoints about the practice. Proponents of prescription DTCA 
assert that the practice empowers the public because patients gain confidence to speak up 
for themselves in a doctor’s office and allows for better communication between doctors 
and patients. In addition, pharmaceutical companies defend DTCA with the claim that 
they are simply educating the public. On the other side o f the issue, opponents argue that 
prescription DTCA is not providing information to patients and is only a slick marketing 
tool to raise revenue for big-name drug companies.
Critics o f prescription DTCA point out that the United States is one o f only two 
countries in the world (New Zealand being the other) which allows pharmaceutical 
companies to advertise directly to consumers. The natural question that arises about 
DTCA is why the United States does not see a problem with this marketing when the rest 
of the world is opposed to it. In response to this question, the spotlight has focused on 
the conflicts that arise in the medical profession when big business (i.e. pharmaceutical 
companies) has an influence on patient choice. Although pharmaceutical companies, 
such as AstraZeneca and Pfizer, claim DTCA empowers consumers by making them 
more assertive in their own healthcare, David Hall argues that “the cloak of 
empowerment is used to hide the maintenance of control in the hands o f the powerful.” 
Most ethical concerns about DTCA revolve around the possible conflict o f interest for 
both the drug companies and the physicians (Henney; Gemperli; Murray).
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Jane Henney specifically questions if  drug marketing can “serve two masters: the 
promotional interest o f the pharmaceutical industry and the public’s health needs” (2242) 
and refers to research that shows the risks in printed prescription DTCA are ignored by 
almost 33% of patients. The fear is that patients are convinced that they know all there is 
to know about a medication when, in fact, they know very little o f the contraindications. 
Marcel Gemperli points out that doctors once were the “learned intermediaries” for 
patients when it came to prescription drugs, but patients today often overlook the advice 
o f these physieians in their quest for the perfeet eure. Many doetors have even admitted 
to eaving into the demands o f the patient in order to keep their business. Murray et al. 
diseuss the ethical implications o f this pressure to please the eustomer in their researeh 
whieh shows “physieians filled 69% of requests (based on DTCA) that the doetors 
themselves deemed elinieally inappropriate” (520). The study also indicates that patients 
“make almost as many inappropriate requests as appropriate ones” (Murray et al 522).
From a legal standpoint, DTCA has rekindled interest in the FDA regulatory 
guidelines established for the practice (Leffler; Turner). Not everyone agrees on whether 
the current laws on preseription drug advertising are adequate, but the general consensus 
is that caution is indicated and ehanges are necessary. Keith Leffler asserts that DTCA 
ean have some positive effects on the welfare o f eonsumers but should not be treated as 
an important souree o f patient information. The most frequent advice given to patients 
on the subject of DTCA is to talk with a physician, which is ironically what the ads 
themselves proclaim. Leonard Weber is cautiously optimistic about the potential value 
for consumer education through DTCA, but advocates significant changes in the current 
system. Weber proposes a change from today’s method of FDA approval after an
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advertisement is published to a control process wherein the FDA must approve all DTCA 
before it appears in front of the public. This idea has recently gained popularity for 
inclusion in a future FDA amendment.
Does DTCA change the doctor-patient relationship?
Although physicians usually made a point of vilifying patent medicine, the general 
public often embraced the language and images in the advertising. For instance, an 
article in an 1881 issue of Scribner’s Monthlv discusses the ongoing controversy of 
patent medicine advertising and the doctors’ fight to prevent patients from endorsing the 
drugs (Holland). The unnamed author of the article points out that many consumers saw 
no difference between the medicines advertised and the prescriptions they could obtain 
from doctors. In a non-regulated market, the consumer was willing to give anyone who 
could promise better quality o f life a chance. In fact, the author’s general opinion was 
that the physicians were envious because they could not gamer as much enthusiastic 
testimony for their remedies as the patent medicine could gather for their advertised 
drugs. The fact that Scribner’s Monthlv focuses on this aspect is not surprising because 
the subject o f testimonials comes up repeatedly in the study of patent medicine 
advertising.
If one issue could be said to dominate the literature on today’s prescription DTCA the 
debate over changes in doctor-patient relationships would be that salient feature. The 
array of written material is clearly divided between opponents of DTCA, usually from a 
physician’s perspective, and proponents of DTCA who claim the practice is beneficial to 
everyone involved.
Physicians, for the most part, agree that they are spending entirely too much time
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“dissuading patients from taking drugs that advertising has led them to believe are 
unproblematic” (Huang). This additional effort on the part of the doctor results in longer 
office visits and increased medical costs. These increased costs are said to not only 
impact the patient directly but also to have an effect on the insurance premiums everyone 
in the general public ends up paying. A particularly worrisome aspect of prescription 
DTCA on doctor-patient interactions is the fear that physicians have about patients who 
might switch caregivers if  the patients’ requests for an advertised drug were denied 
(Kravitz). Therefore, many physicians feel they are forced to react to the marketing 
versus prescribing the medication the patient really needs the most.
This concern has led to a discussion in the last few years of possible “medicalization” 
in the minds of today’s consumers (Hall; Amey & Rafalovich). Under this concept, 
DTCA is believed to have an undeniable influence on what patients perceive is a healthy 
lifestyle. The pharmaceutical ads are said to essentially portray a “medicalized view” of 
the world in which “for every ailment there is a drug to cure it” (Carroll). Patients, 
therefore, often resist the advice from their doctors to exercise or change their diets 
because the patients think a pill is available to do the work for them. In situations such as 
this, doctors are finding consultations with these patients to be very frustrating.
Not all of the literature on prescription DTCA’s impact on the physician-patient 
relationship is negative, however. Elizabeth Murray et al. conducted the first population- 
based survey of physicians and were the first to inquire about the doctor-patient 
relationship in relation to DTCA. The results o f their study illustrate that DTCA can 
have benefits for the patient because the advertising often gives the patient the confidence 
to talk with their doctors. In fact, the perceived empowerment o f patients is often listed
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as the primary reason for allowing DTCA to continue (Keith). Arguments for DTCA’s 
positive influence in the doctor-patient relationship also include the potential opportunity 
for limiting the power physicians have regarding a patient’s choices in healthcare. Many 
times, patients who are aware o f a newly available medication, and who continue to seek 
further information about the drug, end up finding their own answer to a persistent 
problem before their doctor does (Holmer; Kravitz). Naturally, pharmaceutical 
companies agree with this view and argue that they have educated patients so they can be 
more assertive in their healthcare.
As mentioned, most literature on patent medicine and prescription drug DTCA has 
primarily addressed the questions already outlined. However, very few documents 
actually examine the specific discourse in the ads themselves. Existing material on the 
medical discourse o f print advertising is similar to Susan McKay’s writing in which she 
focuses on the language used in health risk articles in popular magazines. McKay asserts 
that “the media add[s] to the understanding of health and medicine in the lay public 
through the coverage o f risk.” McKay concentrates on what the media says in magazines 
versus how the advertising accomplishes its objectives. Hall does not examine DTCA 
directly, but he does analyze a corpus o f medical leaflets which he asserts are nothing 
more than advertisements for prescription drugs. Regarding these leaflets normally found 
in the average physician’s office. Hall asserts, “it might be justified to call this sort of 
generic misrepresentation a pragmatic fraud, since its aim is to induce one kind of 
reaction when ostensibly it presents itself as reassuring or disinterested (and empowering) 
information.”
There are a few notable exceptions to the dearth of discourse analysis o f DTCA
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media, however. Several articles and research studies detail the procedures for a specific 
content analysis o f prescription DTCA. In one such study, Rebecca Welch Cline and 
Henry Young examined the visual cues in a number o f prescription DTC ads and 
provided findings on the nature and consequences o f the images placed in the ads. The 
results show that certain characteristics of the models in the ads along with the rewards 
which are implicit in the photographs significantly influenced the behavior o f patients.
A second study concentrated on the implications of “incomplete syllogisms” included 
in many pharmaceutical ads (Amey & Rafalovich). This research shows that drug 
companies can actually create a major and minor premise for a drug in patients’ minds, 
thus influencing the patients’ conclusion that a drug is indicated for them. This point is 
illustrated with ads that give consumers a number o f symptoms and then ask the 
consumers to check and see if  they have any o f the highlighted symptoms. In most cases, 
the consumers automatically concluded that they had the specified condition and needed 
the company’s advertised drug. Robert Bell, Richard Kravitz, and Michael Wilkes 
performed a content analysis to examine the ways DTCA might target audiences with 
inducements and appeals. The report concluded that drug companies are increasing 
demand for a product, but stated further research is necessary to find the effects on 
doctor-patient interaction. Cline and Young also conclude their article with a statement 
indicating that, while the analysis o f visual cues was beneficial, a much broader analysis 
that includes the textual elements o f prescription DTCA is necessary.
All o f the aforementioned studies, however, do not attempt to find the enduring 
similarities or differences between the non-regulated drug advertising media of the past 
and a corpus of current pharmaceutical ads, nor do the studies discuss any significant
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elements o f situated meaning. As a notable exception, Shirley Stallings specifically 
draws attention to the unchanging nature o f society’s relationship with drug promotion 
and details the traditions which tie today’s healthcare consumers to the patients o f an 
earlier era. The patent medicine makers o f the past innovatively carved out a niche for 
their products, and now pharmaceutical advertising has become a lucrative endeavor for 
big-name drug companies. As the targeted audience for this enterprise, society “needs to 
pay attention and maintain an awareness o f the institutions it has sanctioned” (Stallings 
214). To that end, this thesis ultimately critiques the discursive techniques used to create 
situated meaning in much earlier drug advertising to determine if  these factors are still 
active in the building blocks o f modem DTCA.
Methodology
In studying the discursive methods o f present pharmaceutical DTCA in 
comparison with the non-regulated advertising of patent medicines, I use James Paul 
Gee’s theory o f situated meaning and building tasks as a qualitative foundation for 
examining a corpus o f available print ads. According to Gee, situated meaning is the 
concept that words depend on a particular situation to gamer meaning and that “words 
have different specific meanings in different contexts of use” (53). For each specific 
situation, Gee suggests we examine the discourse for “who doing what” because there 
will always be discursive indicators o f someone establishing an identity (“who”) in order 
to participate in a social activity and achieve a desired outcome (“what”) (Gee 22-23). In 
that regard, Gee’s theory is very similar to Kenneth Burke’s theory o f rhetorical criticism 
because an agent is accomplishing a purpose through the context o f the discourse.
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At first glance, then, prescription DTCA would appear to have the same situated 
meaning as the historical patent DTCA -  a medicine maker (“who”) using a discourse to 
sell a product to consumers (“what”). In fact, physicians typically perceive this similarity 
o f situated meaning to be at the crux of their argument against prescription DTCA and 
see the practice as being an undesired throwback to an earlier time. Pharmaceutical 
companies assert, however, that they are not simply selling a product and are instead 
educating the public through the discourse. If this claim is true, then the situated 
meaning would not be the same for patent and prescription DTCA, and the discourse of 
historical and current medicine DTCA should demonstrate key differences in 
comparison. This thesis thus examines the discourse of both patent and prescription 
DTCA to determine if  there is in fact any real difference in situated meaning.
When doing a discourse analysis of this nature. Gee proposes asking specific 
questions (which will be explained in later chapters) for determining how a discourse, 
such as direct-to-the-public pharmaceutical advertising, might use “building tasks” (10) 
to build identities, establish connections, and privilege certain types o f sign systems and 
knowledge. For the purposes o f this study, patent DTCA will refer to those drugs sold by 
advertising to the public prior to FDA regulation, and prescription DTCA will refer to the 
current, FDA-governed marketing o f pharmaceutical companies. The following chapters 
will use each of the aforementioned building tasks -  identities, connections, and sign 
systems and knowledge -  to compare and contrast patent DTCA’s situated meaning to 
that of today’s prescription DTCA. Although I acknowledge that innumerable over-the- 
counter drugs are also sold through DTCA today, the area o f primary interest for my
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study is the prescription drugs that require a doctor’s involvement because this area is 
under the most scrutiny by physicians and the FDA at the present time.
We can best decide i f -  as critics claim -  the situated meaning of prescription DTCA 
is the same as patent DTCA by breaking down the discourse of the advertisements into 
what Gee calls “building tasks” (10). Chapter two focuses solely on the building task of 
“identity” (Gee 11) to uncover the ways in which authors o f the advertising discourse try 
to position themselves with an audience. A drug maker can use an identity to establish 
rapport with consumers in many different ways. From identity, I move in chapter three to 
the building task of “connections” (Gee 13), illustrating how authors of the discourse 
make certain aspects relevant or irrelevant to the readers. The last individual building 
task this thesis employs in chapter four is “sign systems and knowledge” (Gee 13) which 
is vital to our understanding of the methods authors use in a discourse to privilege 
specific information or awareness. Finally, chapter five pulls together the building tasks 
discussed in the previous chapters to bring “validity” (Gee 113) to our analysis. This 
final step is crucial, as no building task alone should completely influence our analysis, 
and the interaction of individual building tasks within a discourse better enables us to 
make an informed decision about the true situated meaning o f DTCA. If pharmaceutical 
companies are correct in their assertion that the discourse is designed to educate 
consumers about diseases and conditions, we should be able to see a significant 
difference between patent and prescription DTCA.
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CHAPTER 2
BUILDING IDENTITIES 
Like any other type o f discourse, pharmaceutical advertising gains or loses meaning 
through its social interaction and context. Gee, in his theory of discourse analysis, calls 
this fluidity o f purpose “situated meaning” (53) and explains that a discourse’s meaning 
is conveyed through images and text that correspond to a mutually agreed-upon 
connotation between author and audience even though this consensus o f meaning usually 
develops through an audience’s unconscious agreement. Gee asserts that we must always 
look at the “who doing what” of a situation to understand how the discourse goes about 
creating this flexible meaning (22).
One could simply argue then that pharmaceutical advertising, like any other type of 
advertising, is deliberately designed to attract attention and sell a product and therefore 
has the same situated meaning in all cases, but that position does not fully examine the 
advertising discourse to determine if the situated meaning o f today’s prescription DTCA 
is really the same as it was for the historical patent DTCA. We can only find the true 
nature o f “who doing what” (Gee 22) by comparing patent DTCA to prescription DTCA 
and d iscussing  the sp ecific  techniques the ads u se to accom plish  certain goals. To that 
end, this chapter will analyze the ways in which patent and prescription DTCA set about 
establishing an identity with the public, looking under the surface o f the ads to uncover
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the roles and positions medicine marketers assume when conversing with consumers.
In his method of examining discourse, Gee discusses several “building tasks” (10) 
which will typically lay the foundation for any discourse’s construction of meaning.
Each of the building tasks carries with it questions we can ask to determine how a 
discourse aligns itself under the task’s foundational concepts. Gee calls one of these 
building tasks “building identities” (11) and encourages us to answer the following 
questions about identity when examining a discourse:
1) What identity (roles, positions), with their concomitant personal, social, and 
cultural knowledge and beliefs (cognition), feelings (affect), and values, seem to 
be relevant to, taken for granted in, or under construction in the situation?
2) How are these identities stabilized or transformed in the situation? ( I l l )
The underlying principle behind building identities is that creators o f discourse always 
seek to establish a certain role they feel is important to have when speaking to an 
audience. As a result, this role gains the discourse the right to have a voice in the situated 
meaning.
Identity could be compared to the rhetorical appeals to ethos, but takes on a more 
complex definition in the context of Gee’s theory. While the classical appeal to ethos 
involves the persuasive establishment o f qualities intrinsic to the speaker, the building of 
identity in a discourse would mean not only the personal character the discourse is trying 
to establish for the author but also the authority or position the discourse wants the 
audience to recognize it as having in the immediate situation. For instance, Gee uses an 
example of a person leading a business meeting to illustrate the task of building identity. 
In the context of the business meeting, the person would behave and speak in a particular 
way to gain recognition as the “chair,” but would probably not act in the same manner in 
a peer interaction outside the meeting (99). The identity of the chair would therefore be
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situated in the discourse of the meeting.
In the case o f pharmaceutical advertising, we can determine the situated meaning o f 
the discourse by looking closely at the printed ads to find the identities that DTCA from 
past and present construct in order to carve out a position in pharmaceutical marketing.
In selecting patent DTCA for analysis, this study selected two patent medicines -  Lydia 
Pinkham’s Vegetable Compound and Peruna -  which received notoriety in the late 
nineteenth and twentieth centuries for the amount o f money their makers spent on 
advertising and for the criticism their products received in the public media. Despite the 
often negative publicity, these patent medicines were very successful for many decades. 
This study then used the same selection process for prescription DTCA, choosing two 
drugs -  Lipitor and Nexium -  that are extremely popular prescription medications which 
have each made billions of dollars for their makers but have received criticism as well.
We will look at the visual and textual features o f all o f these ads to determine if  they 
establish identity in the same ways. Similarities would indicate -  as many critics suggest 
-  that the discourse’s sole purpose is to sell a product. Any significant differences, on the 
other hand, would indicate that a different situated meaning exists and would support 
pharmaceutical companies’ claims that the discourse is intended to educate the consumer. 
The best place to begin is with a well-known patent medicine to determine how it 
addresses the building task of identity.
Lydia Pinkham and her family began to mass market their proprietary recipe for a 
Vegetable Compound to the public in 1875, and their techniques were so successful that a 
variation of the compound is still sold in some pharmacies today. This patent medicine 
was touted as being effective on the “female complaints” that all women supposedly
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“suffered” (Pinkham, 1875). Typically, the ads for Lydia Pinkham’s Vegetable 
Compound focus on the maladies that accompany menstrual and menopausal symptoms, 
even though the medicine is also declared in the patent DTCA to be beneficial to “either 
sex” when taken for “kidney complaints” (Pinkham, 1892).
In keeping with the medicine’s frequently stated indications for use, the most striking 
visual aspect o f the DTCA for Lydia Pinkham’s Vegetable Compound is the overt effort 
the ads made to establish a strong identity with women in society. Ads appearing from 
1881 to 1906, for example, consistently featured an illustration of a woman at the top of 
the ad where the image would be in a prominent position. The Pinkham family clearly 
saw the value o f using a woman’s image in the Vegetable Compound ads because all of 
their ads contained a drawing of an elderly woman said to be Mrs. Pinkham. The 
matronly woman in the illustration gazes out to the reader with the calm, reassuring 
manner one would expect of a steadfast mother.
The Pinkham family continued to use this female image even after Pinkham’s death 
in 1883, but they were careful to transform the visual identity to match the evolution of 
society. For example, DTCA for Lydia Pinkham’s Vegetable Compound published after 
1895 removed the illustrations o f the familiar elderly woman believed to be Lydia 
Pinkham and replaced them with younger, more attractive “working girls” (Pinkham,
1896). The persistent visual imagery of the ads demonstrates the patent medicine 
maker’s desire to create and maintain the identity of a reputable, contemporary woman 
speaking to other women.
The identity created in the visual elements o f the Lydia Pinkham Vegetable 
Compound ads meshes seamlessly with the textual content o f the marketing. In fact,
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DTCA for this patent medicine in the years from 1881 to 1883 featured headlines in bold 
text o f slogans like “Woman can Sympathize with Woman. Health o f Woman is the 
Hope of the Race” and “A Medicine for Woman. Invented by a Woman. Prepared by a 
Woman” (Pinkham, 1881). One ad in particular which ran for several months in 1892, 
pairs a drawing o f an elderly woman and a younger man reading through letters 
(attributed in the ad to be Lydia Pinkham and her son) with 12 lines o f conversation 
supposedly taking place between the two figures. In the text, Lydia Pinkham states, “The 
women o f the world are my daughters, dear” (Pinkham, 1892). This heartwarming 
scenario perfectly marries visual and text to portray a woman who could not possibly be 
untrustworthy in her medicinal motives. Unfortunately, as many critics have pointed out, 
this specific ad was printed nine years after Lydia Pinkham’s death (Bok, Adams,
Young).
Interestingly, though, the nurturing female persona o f the Lydia Pinkham ads is 
somewhat subverted by the fact that Pinkham never addresses the reader directly in any 
o f the ads even in the years before her death. More specifically, the lack o f first-person 
pronouns or “I-statements” (Gee 141) shows a reluctance to fully engage with the 
audience. This lack of direct interaction can be compared to a speaker who will not look 
into her listener’s eyes during a personal conversation. The listener is naturally going to 
question the truthfulness o f the speaker’s words and the sincerity o f the speaker’s 
concern. In addition, the speaker will convey the impression that she has some ulterior 
motive for distancing herself from the conversation.
So rather than engaging the reader directly, an unnamed narrator consistently refers to 
Pinkham in the third person, the only exception to this rule being an autograph under the
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illustration o f an elderly woman assumed to be Lydia Pinkham in the ads from 1881 to 
1883 that reads “Yours for Health, Lydia E. Pinkham” (see Figure 2). This autograph is 
also one of the rare instances when the ads use a personal pronoun to directly address the 
reader.
H R S . LYDli L  PINKHAM. OF L7NN, M A SS.,
LYDIA E . P IN K H A M ’S
VSGETABLS C0MP0Ü1TI».
Figure 2. Top o f Advertisement for Lydia Pinkham’s Vegetable Compound -  1881
Instead, the ads use first- and second-person voice to deliver positive news to the 
reader in the form of numerous testimonials from grateful female customers. The writers 
of these letters of praise direct their comments to Lydia Pinkham and reinforce her 
position as a woman who was concerned primarily about the health of her female clients. 
One ad, for example, in 1904 consists solely of the usual drawing of a young woman and 
two such testimonials to the value o f Lydia Pinkham’s Vegetable Compound. In the ad, 
one letter from a Miss Merkley commends Pinkham for “the great good you have done 
me” while another letter from a Miss Claussen claims other women should “try Lydia E. 
Pinkham’s Vegetable Compound” because “they will not be disappointed with the
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results” (Pinkham, 1904). The reader, therefore, is allowed to eavesdrop on the 
conversation and receive sisterly advice from the testimonials. This permits the makers 
of Pinkham’s Vegetable Compound to construct an intermediary with the customer.
Another important textual feature o f the patent DTC ads for Lydia Pinkham’s 
Vegetable Compound is the wording the makers use to distance themselves from the 
regular physicians in the consumers’ eyes. To do so, each ad from 1879 to 1906 alluded 
to the unfortunate ignorance of doctors when it came to the worth o f the patent medicine. 
In the 1897 ad, the narrator states, “the usual treatment adopted by physicians.. .is 
unphilosophic, unsuccessful, productive o f great suffering, and in many instances o f fatal 
results” (Pinkham). A testimonial in an 1898 Lydia Pinkham Vegetable Compound ad 
which ran in newspapers for several years proclaimed, “The doctor gave me medicine, 
but it did me no good” (Pinkham). These references to the physicians’ purported inept 
handling of medications complicated consumers’ decisions in a time when little to no 
regulation existed for the advertising o f pharmaceuticals. Thus, the image of a warm, 
motherly figure like Lydia Pinkham contrasted with the impersonal figure of the doctor 
and motivated patients to opt for the patent medicine.
If Lydia Pinkham’s target was the female consumer, then Peruna could be said to 
have had “everyman” as its intended audience, as it demonstrated both visually and 
textually in the patent DTCA. Peruna, another patent medicine with an enormous 
following, made millions of dollars from a diverse group of consumers for its founder. 
Dr. S. B. Hartman. Visually, the ads for Peruna support the notion that the drug was 
targeting a wide range o f patients because the ads tended to use a variety o f people in its 
illustrations. In the years 1885 to 1901, for example, the Hartman company changed
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each ad’s visual element on a frequent basis to show that people o f every gender, age, and 
economic status were happily taking Peruna. To add further credibility, images of 
politicians. Catholic nuns, and celebrities populated the illustrations (see Figure 3).
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Figure 3. Top Portions o f Advertisement for Peruna -  1899 (left) and 1901 (right)
Rather than focus its energy on a limited audience, the Hartman company clearly 
preferred to establish the identity o f a concerned drug maker reaching out to all members 
o f society. Constantly changing the people represented in the ads not only allowed the 
Hartman company to expand its eonsumer base but also sent the message that the product 
was beneficial to everyone. In addition, this visual tactic provided the ads with new 
sourees from which to draw praise for the medication. Even Hartman often must have 
gotten earried away with the testimonials, however, beeause many crities claimed Peruna 
ads featured false praise and forged letters from important members o f society (Bok; 
Adams).
The textual elements o f the Peruna ads also bear a striking resemblanee to the 
Pinkham ads in that we again never see the drug maker reaching out directly to the publie
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in order to sell the produet. The Peruna ads from 1885 to 1901, for instanee, never use 
first-person voiee to address the readers and instead rely on testimonials from numerous 
eonsumers to establish the eompany’s image. Also similar to the Pinkham ads, are the 
testimonials in Peruna’s ads that are written not to the audienee but to the founder of 
Peruna, Dr. S.B. Hartman. For example, an 1899 Peruna ad features a testimonial from a 
Governor Atkinson who tells Hartman, “I ean reeommend your preparation, Pe-ru-na, as 
a tonie.” The reader thus has a ehanee to hear the praise heaped on Hartman’s produet 
without being overtly drawn into the conversation.
Hartman, in fact, does not use the first person in any o f the ads save one which is one 
of many attempts to disparage physicians. This 1886 advertisement (Figure 4) begins 
with the sentence “We do not find fault, reproach, or condemn the practice of any regular 
physicians...” (Peruna, 1886) and goes on to state why a good doctor should prescribe 
Peruna to patients.
To Pbysiclans*
W e do n o t find fault, reproach or con­
demn the practice of any regular physi­
cian—this IS not our mission—hut we do 
claim that if he were to  add Feruka to 
his prescriptions, as directed in our hook 
on tlie “ l ils o f  Life,” (and furnished g ra t­
uitously by  all druggists), h o  would cure 
all his patients.
M r, Henry C , Reynolds, I  ronton, L a w ­
rence County, Ohio, writes! <‘ M y wife 
has been sorely distressed for m any years. 
H er disease o r diseases and the symptoms 
of them have been so varied th a t an  a t­
tempt to describe them would be mote 
than X feel able to undertake. I  Imve 
paid over a  thousand (i,ooo) dollars for 
doctors and medicines fbr her, witliout any 
satisfactory results. W e read so much 
about your Perona th a t  I  was forced to 
try  it. She has now taken five bottles; 
they have done her m ore good than all 
the doctors and medicine that she has ev­
er m ade use of, Peruna is certainly a  
G o d * « e n d  to humanity.”
Figure 4. Top Portion o f Advertisement for Peruna -  1886
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Other, more subtle attacks on physicians are carried out in the testimonials that make 
up the majority o f the layout for every Peruna advertisement. For example, the 1886 ad 
also has a testimonial which asserts a patient had “consulted a number o f physicians, but 
received no benefit whatever” (Peruna, 1886). In effect, Hartman uses the discourse to 
undermine physicians and better position his own product with the public.
As we have seen, the makers o f both Pinkham’s Vegetable Compound and Peruna 
saw the need to do similar things in constructing their identity. First, both medicines use 
visual elements to highlight the loyal following each drug had generated. As a result, the 
patent DTCA relies heavily on visual representations of their existing clientele in the 
discourse. Next, both medicine makers use textual cues to present themselves as 
objective parties who are offering to share the experiences o f others with the eonsumer. 
In doing so, the ads for both medicines use I-statements that are action-oriented (Gee 
141), meaning that the discourse only shows what the authors did instead of providing 
“cognitive” or “affective” (Gee 141) I-statements which would have more personal 
meaning. More specifically, the statements in the testimonials do not tell the reader how 
the users o f Pinkham’s Vegetable Compound or Peruna felt or thought but rather what 
they did in taking the medications. This approach to a product is what we would 
typically expect from advertising’s situated meaning because it asks the reader to make a 
decision based primarily on peer review while preserving the perceived objectivity o f the 
manufacturer.
Finally, both patent medicine makers obviously felt it was necessary to establish a 
clear division between themselves and the regular physicians when building an identity 
with the public. The motivation for this decision is also a good fit for what we would
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typically expect of advertising because no manufacturer wants the customer to go to his 
competitor for advice. And, the physician was definitely the competitor o f patent 
medicines since the doctor was in the best position to dissuade the patient from buying 
the product. Establishing themselves as being more knowledgeable than the physician, 
then, would have been an extremely important role for the medicine makers to assume in 
order to preserve the patent drug business.
So, the ads for Pinkham’s Vegetable Compound and Peruna build identity in ways 
which coincide with what we would normally expect of an advertising discourse. Visual 
images in the patent DTCA mirror the audience the drug makers hope to attract, and the 
textual elements reflect Pinkham’s and Hartman’s tendency to market the patent 
medicines as a commodity versus a personal investment. This separation also allowed 
the makers to avoid a certain amount o f responsibility should anyone have claimed that 
the drugs were not effective. In addition, the discourse shows that Pinkham and Hartman 
wanted to dissuade their audience from visiting their biggest competitor -  the physician -  
which is a logical feature of business advertising.
Today, the authors o f prescription DTCA claim they are doing something different in 
their advertising. The Pfizer pharmaceutical company, for example, stated in its 2007 
report to stockholders that prescription DTCA “educates patients and is a critical 
conversation starter that results in life-changing diagnosis and treatment decisions” 
(Pfizer 84). Another pharmaceutical company, AstraZeneca, told stockholders in an 
annual report that DTCA “plays an increasingly important role in informing healthcare 
professionals and others about AstraZeneca’s medicines and the diseases they treat” 
(AstraZeneca 16). If this is true, then the ways in which they build identity in the
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discourse o f prescription DTCA should be somewhat different than it was for the patent 
medicines already discussed. To see if  a difference genuinely exists in situated meaning, 
then, we must look at prescription DTCA for the same elements of visual imagery, I- 
statements and voice, and physician interaction. In selecting the prescription drugs for 
analysis, this study chose Nexium, an acid-reflux drug made by the AstraZeneca 
company, and Lipitor, a cholesterol-inhibiting drug made by the Pfizer company, because 
both drugs have received significant publicity for the amount o f money AstraZeneca and 
Pfizer have spent on advertising -  $16 million in one month alone for Nexium and $11 
billion in 2006 for Lipitor (Bazell, Mar 2007).
Visually, Nexium and Lipitor establish identity with the audienee in ways that might 
appear ineongruous at first glance, but they contain discursive features shared by all 
prescription DTCA. Nexium’s ads from 2006 and 2007, for instance, always feature 
color photographs o f people from a wide range o f backgrounds, genders, etc., but the 
people in the images are not eustomers who are currently taking Nexium. Instead, the 
photos are o f potential patients who are said to be in desperate need o f the produet, and 
an omniscient voice narrates each image warning of the danger o f an undiagnosed 
condition, such as acid reflux. Since the images are supposedly of people who should be 
taking Nexium, the ads do not have a true testimonial element as patent DTCA once did, 
rather they reflect the ominously directive tone o f the aecompanying text.
This narration lets the readers feel as though they too are peering through a window 
with an increased knowledge of what may come for the poor unassuming person in the 
image. One ad for Nexium, for example, shows an elderly man in a cardigan sweater 
who placidly looks at the reader while the text beside the photo asserts: “Knows that his
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car isn’t the only thing that needs a regular check-up” . . .’’Knows an apple a day won’t 
always keep the doctor away”. . .’’Doesn’t know acid reflux may be damaging his 
esophagus.” (Nexium, Jun 2007). AstraZeneca takes a position o f all-knowing expert in 
the Nexium ads and uses discourse which allows the readers to hear the implied warning 
and feel as though they now have an awareness o f medical issues that they previously had 
not possessed. Using this same concept in all o f the Nexium ads (see Figure 5), 
AstraZeneea appears to share a professional secret with the reader about the unsuspecting 
people in the photos.
Krf*
Knows Î ; H il Id a tt
SS7' r.e" Dû! ic n. 
Knows Jief Lü — aLe b!EïD--Y kera
D o o s i t t  K now
Figure 5. Top Portion of Advertisement for Nexium -  2006
Lipitor, on the other hand, uses the imagery in their ads in a way which is somewhat 
different from the Nexium ads. The Lipitor advertisements use a eolor photograph of a 
patient. Dr. Robert Jarvik, who states he is currently using the product, so the visual is a 
type of testimonial, but the appeal is made directly to the reader versus the appeals of
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patent DTCA which, as we said earlier in this chapter, were made to the drug maker. For 
example. Dr. Jarvik gazes calmly at the readers from one ad (see Figure 6) and reassures 
them that “Lipitor lowers bad cholesterol 39-60%. It lowered mine” (Lipitor, Dec 2007).
^ ^ I J p i t o r  l o w e r s  
c h t > i t ' s l e r o l  
m i i i e V
Ob duar
S!.miEr Jarah
Figure 6. Top Portion o f Advertisement for Lipitor -  2007
The presence of Dr. Jarvik in the prescription DTCA for Lipitor is beneficial to 
Lipitor’s building o f identity for two reasons: 1) Dr. Jarvik is a patient who highly 
recommends the product to other consumers and 2) Dr. Jarvik is a physician and 
“Inventor o f the Jarvik Artificial Heart” (Lipitor, Jun 2007) which increases the perceived 
credibility o f the spokesperson and the product. Dr. Jarvik’s reported expertise in cardiac 
medicine helps Pfizer immensely because he makes a trustworthy and professional 
representative for their cholesterol drug. Criticism of Pfizer’s use o f Dr. Jarvik as a 
spokesperson has included claims that Dr. Jarvik is not a practicing physician and that his 
experience with the artificial heart was significantly overrated (Bazell, Mar 2007), but 
this negative publicity about the marketing campaign has not affected Pfizer’s revenue 
since “Lipitor hit $3.3 billion” (Bazell, Mar 2007) in sales immediately after enlisting Dr. 
Jarvik’s assistance in 2005. In fact, consumers have responded so well that Dr. Jarvik is
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currently the only person featured in any o f the Lipitor ads.
In the language o f the ads, AstraZeneca and Pfizer do seem to want a closer 
relationship with the consumer than patent medicines once had. In fact, the 
pharmaceutical companies build an identity through the advertising which shows this to 
be true. Lipitor and Nexium ads, for example, use an authoritative tone in both the visual 
and textual elements o f the prescription DTCA to bolster their position in the discourse. 
Although AstraZeneca begins with third-person voice for the visual aspect of the Nexium 
ads, it switches to second-person pronouns in the body o f every ad’s text. While no I- 
statements are used, the ads speak directly to the readers giving them an idea of what 
could happen if  Nexium is needed but not used. For example, one ad states, “Unlike your 
stomach, the esophagus offers little protection against acid. This means the heartburn 
pain you feel is actually from stomach acid rising up into the esophagus...” (Nexium, Sep 
2006). Another ad asserts, “If you suffer from acid reflux disease.. .you could have 
serious damage to your esophagus and not know it” (Nexium, Jul 2006) Statements such 
as these are meant to demonstrate to the reader that AstraZeneca can be trusted in its 
knowledge o f medicine and in the indications for Nexium.
Pfizer begins its Lipitor ads with the images of Dr. Jarvik speaking to the audience 
and carries this first-person voice into the body of every ad’s text. The I-statements in 
the Lipitor ads come directly from Dr. Jarvik and are not only action-oriented -  telling 
the consumers what they should do -  but are also what Gee calls “cognitive” (141) 
because Dr. Jarvik gives indications o f what he thinks o f heart attacks, strokes, etc., from 
a doctor’s perspective. In addition, the tone, as in the Nexium ads, is authoritative 
because it speaks to the reader in prescriptive language. For example, one Lipitor ad tells
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the reader, “if  you take LIPITOR, tell your doctor if  you feel any new muscle pain or 
weakness” (Lipitor, Dec 2007). Another ad directs the reader to find more information 
about the medicine through Pfizer’s website.
Another aspect of building identity that appears to be different in the text of 
prescription DTCA is the interaction with physicians that the pharmaceutical companies 
demonstrate they want to have. Whereas the patent DTCA from the past attempted to 
build a separate identity from the doctors, the prescription DTCA makes several attempts 
in each ad to exhibit professional goodwill toward physicians. Nexium ads, for instance, 
repeatedly use lines such as “Ask your doctor if  NEXIUM is right for you” and 
“ .. .discuss it with your doctor” (Nexium, Sep 2006) throughout the text. Of course, 
maintaining an image o f collaborative effort with physicians is important if  the company 
hopes to have its medication sell. After all, physicians must prescribe Nexium and 
Lipitor if  a patent is to take them, and AstraZeneca and Pfizer are careful not to bite the 
hand that feeds them.
To that end, Lipitor ads use similar language, but are interesting in the way they 
continue to have an authoritative voice even while referring a patient to a doctor. For 
example, after directing the consumer to see a doctor, one Lipitor ad states, “Your doctor 
should do blood tests to check your liver function before and during treatment...” 
(Lipitor, Dec 2007). The pejorative use o f the word “should” in this line in relation to 
what a proper doctor would know to do indicates that Pfizer still feels it has the upper 
hand in the discussion o f Lipitor and wants to convey this position to the public.
An element o f today’s prescription DTCA which is impossible to compare to the 
patent DTCA is the full page, or often several pages, of text on the reverse side of the
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printed ads that describes the side effects and risks o f the prescription medications. 
Historically, the patent DTCA never had this feature because the patent drugs were not 
regulated in any way. The FDA, however, now requires that all “product-claim” ads -  
those prescription ads that feature both a medicine’s name and indications -  include a 
lengthy textual component that provides consumers with important information about a 
drug. In this component of the prescription DTCA, however, we usually see the drug 
company’s desired image -  a concerned corporation speaking directly to a potential 
patient -  diluted by the accompanying legal requirements o f the text. Nexium ads, for 
example, commonly begin the reverse side of their ads with the warning to “ask your 
doctor about NEXIUM” (Nexium, Sep 2006). From that point on, the ads revert to a 
detached third-person narrative filled with technical language and legal terms. Likewise, 
the Lipitor ads begin the text for side effects and risks with a conversational tone but 
quickly evolve into a very authoritative voice with statements that begin with prescriptive 
words such as “Do no t...” and “Take....” Pharmaceutical companies therefore have an 
interesting convolution of identities happening in a single discourse due to the FDA rules.
As one can imagine, building an identity in the prescription drug market today is vital 
to a pharmaceutical company’s success, and ironically FDA rules sometimes make 
establishing this identity easier for a drug maker in the discourse o f the ads. For example, 
one common way for a pharmaceutical company to establish its identity is in the strategic 
placement o f ads that don’t even address a particular medical condition. Instead, these 
ads, categorized as “reminder” (Weber 160) by the FDA, are allowed to mention only a 
brand-name drug but not a specific disease, condition, or guidelines for use. By FDA 
regulation, these reminder ads can refer a consumer to a physician, but they cannot
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address any particular indications for the prescription drug in the ad. Therefore, while the 
content of the reminder ad is not designed to overtly sell medicine, it nevertheless invites 
the public to associate a company’s brand name with a positive image.
AstraZeneca, like many other pharmaceutical companies, has found an innovative 
way to build its own identity with DTC reminder ads. Although AstraZeneca follows the 
FDA rules in these ads by including the Nexium name, it also takes the opportunity to 
pitch the company’s ethical appeal. With this unique combination o f reminder and 
corporate-identity advertising, AstraZeneca tries to build its positive ethos by showing 
what the company is doing to be socially responsible. For example, in one such reminder 
ad, AstraZeneca tells readers “NEXIUM users don’t have to go far for free support” and 
encourages the reader to “Be part o f Purple Plus -  a free program for NEXIUM users” 
(Nexium, Sep 2006). The ad then goes on to tell the reader how AstraZeneca can help 
them save money when purchasing the drug. Although this particular Nexium ad does 
mention getting advice from doctors, these hybrid ads often omit any reference to a 
physician and could be compared to public service announcements from agencies who 
profess an altruistic dedication to overcoming a social dilemma.
AstraZeneca and Pfizer are very diligent about carrying over the positive image 
created in their reminder ads to the text of their more traditional ads. All product-claim 
DTCA for Nexium, for instance, contains a three-line entry at the bottom of the ad that 
reminds the reader about Nexium’s “Purple Plus Program” encouraging the reader to call 
for more information. The small print under this reminder informs the reader that 
AstraZeneca might be able to help users of Nexium with their prescription costs. Pfizer 
uses the same concept in its product-claim DTCA for Lipitor, ensuring the reader knows
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about its “helpful answers” (Lipitor, 2006) program that can help uninsured patients with 
funds for their Lipitor prescriptions. So, pharmaceutical companies like AstraZeneca and 
Pfizer now use FDA rules to create a unique marketing situation wherein the image o f 
monetary assistance from a benevolent company is clearly highlighted for a needy 
customer.
As consumers, however, we must remember what Samuel Hopkins Adams said in 
The Great American Fraud — “It is safe to assume that every advertising altruist who 
pretends to give out free prescriptions is really a quaek medical firm in disguise” (62) -  
beeause the discourse o f prescription DTCA should not always be accepted at face value. 
After all, the FDA continues to enact laws which strongly regulate the marketing 
practices o f prescription DTCA. So, while AstraZeneea and Pfizer do appear as though 
they are acting out of concern and compassion in their advertising discourse, they also 
include specific textual elements simply beeause the FDA tells them they must do so if 
they want their ads published. For instanee, the rejoinders in the prescription DTCA to 
“see your doctor” or “discuss this medication with your doctor” are not altruistic 
decisions made solely by the pharmaceutical companies. Rather, the FDA mandates that 
these types o f statements be included in every product-elaim ad that is published in the 
mass media.
In terms o f situated meaning, however, prescription DTCA does reflect key 
differences compared to patent DTCA in the way both discourses build identity. The ads 
for Pinkham’s Vegetable Compound and Peruna, for instanee, exhibited language which 
made them sound more like second-hand news from a disinterested reporter. We also 
saw how the patent DTCA used imagery and language to highlight the patients who were
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already taking the medication, hoping that the testimonials would have a bandwagon 
effect on other consumers. Apparently, the patent drug makers did not feel that they 
needed to engage directly with potential consumers or include them in a discussion in 
order to sell the medication. In effect, the patent DTCA does not give the impression that 
the makers genuinely eared about the readers.
The visual and textual eomponents of the preseription DTCA, on the other hand, do 
indicate the drug makers’ desire to include the reader in the marketing and typically 
focuses on people who are not taking the medication. This shows that the pharmaceutical 
companies feel the need to insert themselves in a dialogue with potential patients in a 
way that makes the eonsumers feel as though they are involved in a medieal decision 
versus simply engaged in a commereial produet selection. This interaction with 
consumers would support the pharmaceutieal eompanies’ position that they are using the 
advertising diseourse to edueate the publie.
Therefore, the preseription DTCA does seem to be undertaking a diseourse within a 
situated meaning that is somewhat different from the context o f the patent DTCA; 
however, we must be careful about agreeing to this differenee after only looking at the 
building task of identity. Establishing identity is only one o f many behaviors occurring 
within a discourse, so we must look at other building tasks to fully validate an analysis. 
Therefore, for pharmaceutieal advertising, we ean also look at the ways in which the 
DTCA builds eonnections, and the next chapter will diseuss this aspect o f the diseourse.
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CHAPTER 3
BUILDING CONNECTIONS 
As previously explained, a discourse clarifies its situated meaning -  the “who” doing 
“what” -  through its construction o f certain “building tasks” (Gee 10). This thesis has 
already shown how a discourse like pharmaceutical advertising establishes its identity 
and what the authors’ position can tell us about the context and desired effect, but we also 
need to look at other building tasks to truly determine a particular situated meaning. The 
building tasks function independently, but they also work in combination to signify a 
context. To that end, this chapter focuses on the building task of “connections” (Gee 12- 
13) to analyze pharmaceutical advertising and determine if the situated meaning of 
prescription DTCA is any different -  as the pharmaceutical companies often claim -  from 
the situated meaning of the advertising discourse used for historical patent medicine.
Just as he did in his explanation on the building task of identity. Gee provides us with 
several questions about connections that any good analysis of a discourse will ask. In 
regard to building connections. Gee suggests we examine a discourse with the following 
thoughts in mind:
1) What sorts o f connections — looking backward and/or forward — are made 
within and across utterances and large stretches o f the interaction?
2) What sorts o f connections are made to previous or future interactions, to other 
people, ideas, texts, things, institutions, and Discourses outside the current 
situation?
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3) How do connections.. .help (together with situated meanings and Discourse 
models) to constitute ‘coherence . . .. (112)
Asking these questions will help us determine how a discourse makes its content 
pertinent (or not) to a current or future situation. To further explain the concept of 
building connections, Gee returns to his example o f the person leading a business 
meaning (discussed in this thesis in chapter 2). In the context of the business meeting, 
the person leading the meeting behaves and speaks in a particular way to gain recognition 
as the chair; thus the identity of the chair is situated in the discourse of the meeting. At 
the same time, the person leading the meeting would use specific language to make what 
he/she says during the course o f the meeting relevant (or not) to a time outside of the 
meeting (Gee 100-101). For example, if  we wanted people attending a meeting to, at a 
future date, make an operational decision about hiring practices based on the company’s 
vision, we would need to ensure we use language in the meeting that could help the 
attendees draw that connection later. In a way, building connections is similar to planting 
a seed in a discourse and then implying to an audience why they should help that seed 
grow. In doing so, discourses often use emotional appeals to pathos to bolster the 
connections they create.
A discourse can build (or break, for that matter) certain connections in many different 
ways. Gee states that he prefers to start looking for connections by first finding the 
“motifs” (153-155) that seem to act as running themes in a discourse because the motifs 
indicate ideas the author wants to reinforce with an audience and tie different parts o f the 
discourse together. As this is a good place to start, this chapter will look for the motifs in 
pharmaceutical advertising, again using the patent DTCA for Lydia Pinkham’s Vegetable 
Compound and Peruna along with the prescription DTCA for Nexium and Lipitor as
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specific artifacts for study. Using these same ads throughout this thesis is important 
because we must remain consistent in the analysis examples we use if  we want to reach a 
valid conclusion. In the process o f finding language that establishes motifs, this chapter 
will also explore how the construction of the discourse’s language helps make it easier or 
more difficult for an audience to find relevance in the advertising. We will pay particular 
attention to the use of syllogisms and phrasing in both patent and prescription DTCA 
because these textual elements often are the most effective at facilitating an audience’s 
acceptance of a drug (Amey & Rafalovich). Marketers often rely on syllogistic premises 
in the text to help a reader reach a conclusion that seems logical.
Returning to the patent medicine of the past, we find that common motifs existed in
the advertising for both Lydia Pinkham’s Vegetable Compound and Peruna. The first of
these predominate motifs was that certain health issues were universal to all readers. For
the Pinkham company, this appears to have meant that simply being o f the female gender
was a health issue because the advertisements usually stated the patent drug was good for
all manners o f “female complaints” (Pinkham, 1879) or “female weaknesses” (Pinkham,
1883). In making such female problems more specific for the reader, the DTCA for
Pinkham’s Vegetable Compound typically described a wide variety o f health issues that
were open to interpretation. For example, the ads from 1879 to 1906 contain references
to everything from fibroid tumors to women’s “organic derangement” which a 1906 ad
said was particularly terrible (see Figure 7). This ad was amazingly comprehensive in its
indications when it stated the patent drug was good for:
Irregular suppressed or painful periods, weakness, displacements or ulceration, 
that bearing-down feeling, inflammation of the female organs, backache, bloating 
(or flatulence), general debility, indigestion and nervous prostration, or...such 
symptoms as dizziness, faintness, lassitude, excitability, irritability, nervousness.
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sleeplessness, melancholy, “all gone” and “want-to-be-left-alone” feelings, blues, 
and hopelessness. (Pinkham, 1906)
With such a disparate list o f symptoms, the ad effectively made it possible for any
woman to see that she should include herself in the vast majority o f female consumers
who have what Pinkham’s medicine terms significant health problems.
Both Symptoms of Orgamlc Derangement In 
Women—Thousands of Sufferers Find Relief.
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Figure 7. Advertisement for Lydia Pinkham’s Vegetable Compound -  1906
For its patent DTCA for Peruna, the Hartman company took the same approach on 
this theme that conditions were universal and that everyone suffered at least one of the 
drug’s stated indications. In fact, p inning dow n a sp ecific  illn ess that Peruna w as  
designed to treat is difficult because the ads from 1885 to 1901 ranged from discussions 
o f “catarrah” (Peruna, 1885), which is essentially a form o f sinus congestion, to “kidney 
complaint and dizziness” (Peruna, 1886) and “fever and ague” (Peruna, 1901). The
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patent DTCA for Peruna even gave a nod to the same premise the Pinkham ads 
established for female problems by linking Peruna to “female catarrh” (Peruna, 1899) -  
asserting women have sinus congestion that differs vastly from that o f a man -  and the 
“weaknesses peculiar to” the female sex (Peruna, 1899).
Overall, however, the Peruna ads consistently showed audiences of all ages and 
genders that certain health issues were common to society as a whole. In keeping with its 
“everyman” identity (as discussed in chapter 2) when building connections, Peruna used 
wide-ranging conditions that were sure to have at least one link to each person. Thus the 
wording of the patent DTCA across multiple examples conveys the coherent thought that 
consumers should see their own health as connected to that o f others with the same 
symptoms. Establishing this bandwagon connection was important in the situated 
meaning of patent DTCA because the audience was able to see themselves in the 
discourse and relate their own everyday experiences with the effects mentioned in the 
ads.
The next m otif -  that everyday health issues, although common, were not conducive 
to a happy life and needed to be “cured” -  ran throughout the patent DTCA discourse to 
connect the illness to the medicine. In the ads for Lydia Pinkham's Vegetable 
Compound, for example, the word “cure” was used repeatedly in each ad to show what 
the medicine supposedly had the power to do. In fact, one ad began with the large-font 
heading “Female Complaints and successful METHOD OF CURE” (Pinkham, 1879) and 
employed a version of the word “cured” a total o f eight times in a single 2x8-inch space. 
By telling readers that Lydia Pinkham's Vegetable Compound could cure “the blues” 
(Pinkham, 1906) and other vague symptoms, the patent drug makers effectively sent the
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message to consumers that what they might be feeling was not acceptable and therefore 
had to be fixed. O f course, the only way to correct the problem, according to the drug 
maker, was to use the advertised patent drug.
To someone who is closely reading the patent DTCA, the two motifs of common 
conditions and necessary cures might appear incongruous at first. The natural question 
would be: How could readers accept that health issues shared by all could also be 
abnormal? The answer resides in the syllogism which results from the patent DTCA’s 
construction. The first motif, for instance, establishes the major premise that all people 
share a certain set o f physiological or emotional conditions. Readers can easily situate 
themselves within this premise because they correspond to the targeted group. The 
second m otif then establishes the minor premise that the stated condition means 
unnecessary suffering that can be “cured” with the advertised drug.
The major and minor premise, working together, lead readers to make the concluding 
premise that they have the condition and need à remedy. In the Pinkham ads, for 
example, after telling a female consumer that 1) All women have particular health issues 
(major premise) and that 2) These issues do not need to be endured and can be cured with 
the Vegetable Compound (minor premise), the discourse silently encourages the female 
reader to reach the conclusion o f “I am a woman. I have this problem, so I need this 
medicine -  and lots o f it -  in order to live well.” A Peruna testimonial made this type of 
syllogistic construction evident in the simple statement, “If others who have been sick are 
now well and happy, why shouldn’t you be?” (Peruna, 1889). Using language to 
“medicalize” a perfectly normal health condition, the patent drug makers benefited from 
society’s ability to make assumptions. James Young points out that patent DTCA
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“recognized that nearly every man is vulnerable to the power o f suggestion and sought to 
make him sick so they could make him well” (184). As we will see later in this chapter, 
drug makers are still using syllogistic construction to accomplish the same goal.
In the ads for Peruna, the Hartman company again mirrors the efforts of the Pinkham 
ads in the motif that common conditions degraded a consumer’s quality of life and had to 
be eliminated. The Peruna ads also employed repetitive language, such as the word 
“eure,” to connect various health problems to the recuperative effects o f the drug. One 
such ad begins with the heading “A FAMOUS MUSICIAN Cured of Catarrh and La 
Grippe by Peruna” (Peruna, 1901) and continues in a testimonial to say how glad the 
person is that the wonder drug has at last cured him of his problems. Another Peruna ad 
goes even further in linking illness to a eure in a testimonial which asserts, “It has robbed 
the grave o f one victim, for I was in a critical condition...” (Peruna, 1899).
The unique aspect o f the Peruna patent DTCA, however, is that the discourse o f the 
ads not only ties the drug to possible problems the readers might have had, but also draws 
a strong correlation to the amount o f the so-called cure which might be necessary. In 
very specific language, the Peruna ads tell the audience that using multiple bottles of the 
patent medicine would be the best way to eradicate a health concern. For example, an 
1885 ad mentions that a woman “has now taken two bottles, and is so much better that 
she will never quit its use until she is entirely well” (Peruna, 1885). Another ad a year 
later features a testimonial about a woman who “has now taken five bottles...” (Peruna,
1886). This language continues throughout the Peruna ads often mentioning the use of 
several bottles of the drug (see Figure 8) and in 1899 culminates in a testimonial wherein 
a woman claims she has “taken ten bottles o f your Pe-ru-na and will continue taking i t . ..”
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(Peruna, 1899). None of the ads ever address, however, why multiple bottles or 
continued use might be necessary if  the drug was, in fact, a genuine cure. O f course, 
critics often pointed out that Peruna was approximately 28 percent alcohol (Adams; 
Young; Bok) and Lydia Pinkham’s Vegetable Compound was around 20 percent alcohol 
(Bok), so patients were often willing to take more and more o f the products with very 
little encouragement beyond the first bottle.
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Figure 8. Advertisement for Peruna (aka Pe-ru-na) -  January 1899
While the patent DTCA for Peruna might have been somewhat humorous in its 
methods to sell increased amounts of its product, the advertising discourse has a more 
serious effect in building connections. Gee points out that a discourse has the power to 
influence what he calls “prototypical simulations” (95-96). A prototypical simulation is
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the image or story that a person carries in his/her mind about what a typical situation 
would look like. The person then uses this simulation to determine whether something is 
“normal” or not. For instance, each o f us has a prototypical simulation of what is typical 
or normal for a wedding or for parenting, etc (Gee 95-96). If we were to then attend a 
wedding that did not match up with our prototypical simulation, we would either be 
confused by the juxtaposition or we would have to adapt to the change.
In the same way, patent DTCA established connections which may have influenced 
consumers’ prototypical simulations about healthcare. More specifically, the advertising 
for both Peruna and Lydia Pinkham’s Vegetable Compound demonstrated an effort to 
change what readers comprehended as being normal for everyday health. For instance, 
what women may have originally seen as just being a bad mood became -  through patent 
DTCA -  normalized as a problematic and worrisome female issue. After the consumers 
made the shift in their thinking to what should he normal or typical, it was a short jump 
for them to assume it was then normal to need large doses o f an advertised medication.
At this point, we might expect an audience to seek a doctor’s advice before blindly 
accepting the need for a medicine, but the patent DTCA used a final motif which served 
to break or mitigate any connection readers might have had with a physician. In fact, the 
discourse made the need to see a doctor irrelevant with statements that showed the 
“medical arts” (Pinkham, 1879) had been ineffective and thus were not necessary. Lydia 
Pinkham’s Vegetable Compound ads typically broke the connection between patient and 
doctor by stating frequently that the “female complaints” had “baffie[d] the skill o f the 
best medical men” (Pinkham, 1885) and that doctors gave medicine which had no effect 
on the illness (Pinkham, 1898). Interestingly, a Pinkham ad in 1883 departed from this
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approach by claiming “PHYSICIANS USE IT AND PRESCRIBE IT FREELY,” but the 
Pinkham family, under heavy scrutiny, quickly dropped this line from the advertising the 
following year.
The Peruna ads followed suit in the effort to disrupt the patient/physician relationship 
and often discussed the futility o f seeing a doctor. A testimonial in 1885 informed the 
reader that the patient “had consulted every physician far and near” (Peruna, 1885). 
Obviously, since the patient was now speaking on behalf of Peruna, the doctor visits had 
been unsuccessful. Another testimonial in 1886 proclaimed, “I have paid over a thousand 
(1,000) dollars for doctors and medicines...without any satisfactory results” (Peruna,
1886). Thus the reader is encouraged to save money on doctor bills and buy multiple 
bottles of Peruna instead. Later Peruna ads were even more overt in their attempt to 
dissuade consumers from visiting doctors. Statements such as “I did not call the doctor, 
but used your medicine” (Peruna, 1899) littered the text of patent DTCA to further the 
drug makers’ efforts to make traditional medical care irrelevant.
As we have seen, in terms of situated meaning, the patent DTCA built connections in 
ways that correspond to the basic advertising context o f a manufacturer marketing a 
product to the public. In this case, the drug makers primarily wanted to increase sales by 
showing audiences they absolutely needed their medicine. The first step in doing that 
was to help the consumers see that they were part of the population who had a certain 
condition. Next, the advertising had to guide the consumer into the realization that the 
product would help overcome the health problem they possessed. To accomplish this, 
Lydia Pinkham’s Vegetable Compound and Peruna worked to make the consumer feel 
included through syllogistic reasoning. Finally, the advertising sought ways to prevent
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any interaction potential buyers might have in the future with the competition -  who in 
this ease was the physician. Doing so effectively loeked the buyers into repeated 
transaetions with the manufaeturer.
Like patent DTCA, advertisements for today’s prescription medications also build 
connections in the diseourse, so we ean turn to the ads for Nexium and Lipitor to 
determine how the eurrent pharmaeeutieal companies make eertain elements relevant (or 
not) to the public. Just as we did with the DTCA for Pinkham’s Vegetable Compound 
and Peruna, we will look for the motifs featured in the ads along with the construction of 
the textual elements.
In the first noticeable motif, we can certainly hear eehoes of the historical patent 
DTCA because the most salient feature o f preseription DTCA is the theme that readers 
are not aware of the health dangers that are eommon to our society. AstraZeneea, for 
example, uses language that implies no matter how well a person thinks he/she is 
managing acid reflux, serious problems are still imminent. The Nexium ads, as we 
discussed in ehapter 2, typieally begin with the visual image of a normal-looking person 
who is blissfully unaware of how much he/she might be in jeopardy. We said this image 
helps AstraZeneea draw the audienee in as a silent observer to this person’s woes.
To help build a connection, however, the drug maker switehes in the text o f the ad to 
statements such as, “Even if you’re treating your heartburn, you may still have damage” 
(Nexium, Sep 2006) and “If you suffer from aeid reflux disease...you eould have damage 
to your esophagus and not even know it” (Nexium, Jan 2007). The ads now enable the 
consumer to make the leap from bystander to aetive partieipant by appealing to the fear 
readers might have of their own undiagnosed problems. One ad for Nexium espeeially
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plays on this fear by stating, “IT’S DIFFERENT FOR PEOPLE WITH ACID REFLUX 
DISEASE. Because beneath the heartburn, something more could be brewing” (Nexium, 
Jul 2006). Suddenly, readers make the connection that their oeeasional episode of 
heartburn -  whieh, in faet, might result from a bad meal -  is nothing less than the chronic 
condition exhibited in the preseription DTCA. They begin to see themselves as the 
unfortunate person in the ad’s graphie. If readers were to look more elosely at the text of 
the Nexium ads, however, they eould see that AstraZeneea also seleets its wording very 
earefully.
In faet, today’s pharmaeeutieal companies are much more cautious than the patent 
drug makers were in the wording o f the diseourse. The patent DTCA was unregulated, so 
just about any el aim could appear in the ads with impunity. Preseription DTCA, 
however, must conform to FDA laws or it can and will be held liable for false or 
misleading statements. This is not to say that the ads do not manipulate shades of 
meaning, however. The language in the prescription DTCA, for instance, consistently 
takes advantage o f numerous modal words like “eould,” “may,” and “might” throughout 
the advertising space to not only avoid any absolutes whieh might violate FDA regulation 
but also defleet any blame for misdiagnosis. A good example o f this concept is a line 
which appears in every Nexium ad -  “This condition may affect 1 in 3 people with acid 
reflux disease, and if left untreated, could get worse” (Nexium, Jun 2007). This wording 
choice maintains the ads’ relevance for possible users of Nexium while not specifically 
telling the consumers that they have a problem. The phrasing of sentences in Nexium 
ads also evinces a tendency to place a warning about imminent danger above the more 
comforting words of the discourse. For example, the common heading in Nexium ads -
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“Even if  you’re treating your heartburn, you may still have damage” (Nexium, Jun 2007) 
-  phrases the information in such a way that emphasis is placed mainly on the potential 
damage and discounts the fact that the patient might be trying to treat the condition 
already.
Pfizer, in its Lipitor DTCA, is slightly more encouraging on this m otif of cautioning 
the ignorant consumer but, like the Nexium ads, still seems to offer more warning than 
enlightenment. The Lipitor ads typically list a number o f items they identify as risks for 
heart disease and tell the readers that they could be in danger if  they have “multiple risk 
factors” (Lipitor, Jul 2006). These factors range from something as arbitrary as “age” to 
more specific issues such as “high blood pressure” (Lipitor, Dec 2007). The confusing 
aspect with this approach, however, is that some Lipitor ads state the patient would need 
to show “multiple risk factors” -  no quantifiable number is given -  to need Lipitor, while 
other Lipitor ads state the patients would only need “type 2 diabetes and at least one other 
risk factor” (Lipitor, Nov 2007) to be a candidate for the drug. This discrepancy leads the 
consumers to resolve the difference by erring on the side o f caution and accepting the 
need for the drug on the smallest provocation. In fairness, this study found that the 
Lipitor ads do let readers know that Lipitor may not be indicated in some cases, but only 
lists “those with liver problems” and “women who are nursing, pregnant, or may become 
pregnant” (Lipitor, Dec 2007) as the exemptions. This, of course, leaves a large 
population who could be potential buyers of the drug, and the wording throughout the 
Lipitor ads helps make that choice more obvious.
Once patients acknowledge that they probably have to be concerned with one of more 
of the health issues identified in the prescription DTCA, they will notice the next motif
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which appears in the advertising discourse and is very similar to the non-regulated patent 
DTCA -  the realization that only the advertised prescription drug will help them. To that 
end, Pfizer goes to great lengths in the discourse to make sure the public sees Nexium as 
being very relevant to an acid-reflux condition. The image of an actual Nexium capsule 
appears at prominent positions within the textual component of each ad to reinforce the 
medicine’s shape and color for the readers (see Figure 9).
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Figure 9. Bottom Portion of Advertisement for NexiUm -  2007
In addition, the words, “The Little Purple Pill,” run through every ad and even show 
up in the name o f the customer-service website -  www.purplepill.com -  for the 
medication. These words and graphics work together to solidify the connection in the 
consumers’ minds between their condition and the medication that they should request. 
AstraZeneca also includes references frequently throughout the ads to the recuperative 
power o f Nexium with statements such as “NEXIUM is the healing purple pill” (Nexium,
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Jul 2006) and “it [Nexium] can also heal the most severe erosions in the esophagus.. .” 
(Nexium, Jun 2007). The ads do not mention whether any other options are available for 
treatment.
Pfizer structures its ads for Lipitor to accomplish the same objective o f brand 
recognition. Lipitor is strongly portrayed as being the answer to the consumers’ eoneems 
about heart disease and cholesterol. To support these claims, all o f the DTCA for Lipitor 
pictures Dr. Robert Jarvik -  again personifying the Pfizer corporation as part o f the 
company’s identity — offering numerical data such as “Lipitor lowers bad cholesterol 39- 
60%” (Lipitor, Dec 2007) and “Lipitor reduces risk of stroke by 48%” (Lipitor, Dee 
2007) whieh serve as a convincing “scientific” tool to equate efficacy with the drug.
Each Lipitor ad also includes the line “Lipitor is one o f the most researched medicines 
with over 400 ongoing or completed clinical studies” (Lipitor, Nov 2007).
Of course the Lipitor ads do not make relevant the faet that there have been so many 
studies of the drug partly because it has been under heavy scrutiny by the FDA. In faet, 
several lawsuits in the past have taken Pfizer to task for the claims in the Lipitor ads, 
including one suit whieh recently even tried to subpoena Dr. Jarvik. This suit, filed in 
April 2007 by several labor unions, accuses Pfizer o f knowingly using language in the 
Lipitor ads whieh resulted in a large number o f patients requesting (and often receiving) 
the drug when it was not indicated. The litigation primarily centers on wording that 
shows Pfizer marketed the drug to consumers with an “LDL cholesterol level of 130 
ml/dL” when medical professionals suggest cholesterol levels only indicate intervention 
at “160 ml/dL” (Edwards 14). The labor unions insist that Pfizer’s ads have resulted in 
approximately 40 million people taking Lipitor when not medically necessary (Edwards).
54
The statistics have been in dispute for a while now, but the numbers are unquestionably 
persuasive to readers who make conclusions on what they believe is scientific 
information. In addition, Pfizer’s “helpful answers” campaign -  mentioned in our 
discussion of identity because the reference is included in every Lipitor ad -  aets here as 
a bridge since the customer now not only remembers the company as having a positive 
image but also connects that positive ethos to convincing numerical data in their attempts 
to make a logical healthcare choice.
In helping readers make selections, the construction of the sentences in prescription 
DTCA shares much in common with the patent DTCA. Earlier in this chapter, we said 
patent DTCA helped normalize common feelings, such as a bad mood, into what people 
came to see as a condition that needed to be treated. This same concept works in today’s 
preseription DTCA as consumers change their prototypical simulations of illness based 
on the advertising they read. Like the patent advertisements, prescription DTCA often 
uses syllogistic language to accomplish this change in normality. To explain this idea, 
Jennifer Amey and Adam Rafalovich conducted a study of prescription DTCA that 
showed the overwhelming use o f “incomplete syllogisms” (49) in the wording of the 
advertising made a significant difference in the “medicalization” (50) of health 
conditions. According to Amey and Rafalovich, prescription DTCA almost always 
offers a major premise which invites readers to identify with stated conditions. Then, a 
minor premise helps frame the condition as being symptomatic of a condition needing a 
medicinal remedy. The concluding premise is unstated, but the major and minor 
premises work together to convey “a narrative that paints the concluding premise as 
almost inevitable” (Amey and Rafalovich 57). The ads for Nexium and Lipitor exhibit
55
this type of construction mainly in the form of hypothetical syllogisms -  premises that 
use an “i f ’ statement -  that range from “If you suffer from aeid reflux...” and “if  left 
untreated...” (Nexium, Jan 2007) to “if  you have multiple risk factors...” (Lipitor 2006). 
Pfizer, for one, asserts that its DTCA helps “de-stigmatize disease” (Magee 4), but 
leading consumers to a conclusion also changes their expectations.
In terms o f breaking or mitigating connections, preseription DTCA does not follow 
patent DTCA in its efforts to disrupt the relationship with physicians, but the current ads 
do make certain information irrelevant in the discourse. O f course, we must first 
remember that the FDA mandates the inclusion o f statements like “talk to a doctor,” so 
the historical ads had more freedom to discount doctor intervention. Preseription DTCA 
instead typieally downplays options, other than the advertised drug, whieh exist to 
manage a condition. One clear example of this approach is to mitigate the importance of 
diet and generic drugs. AstraZeneca’s ads for Nexium always begin with the message 
that aeid reflux “despite treatment and diet change” (Nexium, Jan 2007) could be 
damaging the reader’s esophagus while Pfizer’s ads for Lipitor ensure patients know that 
“diet and exercise” (Lipitor, Dec 2007) may not be enough to avoid the need for 
medicine.
Nowhere in the advertising diseourse for either company is any information to 
educate consumers on the proper diet they should consider or the availability o f other 
medications. In fact, Kravitz notes that “patients may become angry when their 
physician insists on a low-fat diet...” and “1 study found that as many as half o f patients 
would register disappointment, and 15% would consider switching physicians, if  their 
physician refused a request for an advertised prescription medication” (Kravtiz 2244). In
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regard to forms o f treatment other than the advertised drug, Dr. Robert Jarvik is featured 
in one Lipitor ad telling the audience that “I take Lipitor instead o f a generic; There is no 
generic form of Lipitor. If you switch, it will be to a generic o f a different medication” 
(qtd in Huckman 1). Language such as this strongly devalues less expensive options than 
Lipitor in the consumers’ minds and enables Pfizer to continue posting Lipitor sales of 
over $13 billion per year (Bazell, Mar 2007).
Interestingly, prescription DTCA also mitigates the very elements which would 
support pharmaceutical companies’ claims that they might be educating the public in the 
discourse. For instance, the reverse side o f the product-claim ads (see Figure 10) that 
must contain the listing o f side effects and risks has the potential to convey extremely 
important information to consumers.
Figure 10. Reverse Side o f Advertisement for Nexium -  Sep 2006
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In the Nexium ads, however, this text is so crowded and linguistically dense that many 
patients -  up to one-third according to Henney -  do not even attempt to read the 
information, thus making the print practically irrelevant to the situation. Instead, patients 
simply remember the drug’s brand name and go to doctors asking for the medication with 
only a surface understanding of the details.
In the case o f Lipitor advertising, the design o f the reverse side o f the product-claim 
DTCA has the potential to make the most serious side effects of the drug irrelevant to 
both patients and physicians. In 1979, the FDA hegan to mandate that pharmaceutical 
companies place “hlack hox warnings” (FDA 9) on labeling to indicate the most severe 
side effects o f a particular drug. As part o f that requirement, drug makers must include a 
hlack border around the text that informs readers o f the most dangerous aspects of a 
medication. According to FDA guidelines, the hlack hox warnings are supposed to 
indicate that;
There is an adverse reaction so serious in proportion to the potential benefit from 
the drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction) 
that it is essential that it he considered in assessing the risks and benefits of using 
a drug
OR
There is a serious adverse reaction that can be prevented or reduced in frequency 
or severity by appropriate use of the drug (e.g., patient selection, careful 
monitoring, avoiding certain concomitant therapy, addition of another drug or 
managing patients in a specific manner, avoiding use in a specific clinical 
situation)
OR
FDA approved the drug with restrictions to assure safe use because FDA 
concluded that the drug can he safely used only if distribution or use is restricted 
(e.g., under 21 CFR part 314, subpart H, § 314.520 “Approval with restrictions to 
assure safe use”).
A boxed warning can also he used in other situations to highlight warning 
information that is especially important to the prescriher. Information included in 
the WARNINGS AND PRECAUTIONS and CONTRAINDICATIONS sections 
should therefore be evaluated to determine whether it should also be placed in a 
boxed warning. (FDA 9)
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Although the FDA has not made the labeling requirements for black box warnings a 
mandatory part o f DTCA yet, many prescription ads use the black borders in their layout. 
The design o f the Lipitor ads, however, features all of the text on the back of the product- 
claim ads in black boxes (see Figure 11). With this format, all of the side effects and 
risks are treated equally and highlighted without discretion in the discourse. Therefore, 
nothing truly stands out or is made relevant to patients and doctors because they become 
accustomed to seeing everything in black borders. Not only does this lack of connection 
to serious warnings prove more time consuming for busy physicians who must search 
through the text for meaningful data, but it also could prove dangerous to the health of 
confused patients.
Figure 11. Reverse Side o f Advertisement for Lipitor -  Dec 2007
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Corning back to the purpose of our analysis of prescription DTCA’s situated meaning 
as compared to the situated meaning o f historical patent DTCA, we can see that there are 
a few differences between the two discourses. Unfortunately, these differences do not 
support the pharmaceutical companies’ claims that they are using DTCA to educate 
consumers about conditions or diseases. Instead, any significant changes in the ads -  as 
compared to the historical ads -  typically result from factors which are essentially beyond 
the companies’ control and reflect how businesses react to potential legal issues that 
impact drug advertising. For instance, prescription DTCA’s frequent use o f modal verbs 
to soften their claims about medications and advisory statements to consult physicians are 
elements we did not see in patent DTCA. However, the drug companies use these new 
elements as a way to avoid sanctions by the FDA versus as a tool for educating readers. 
We also saw how the FDA laws have made the addition o f side effect and risk listings a 
part o f prescription DTCA, but the pharmaceutical companies only comply with the 
necessary information that focuses on the advertised drug. The companies rarely offer 
any additional information that does not directly relate to the medication. As a result, the 
reverse side o f product-claim ads hardly encourages close reading, and consumers often 
find it difficult to glean any substantial information about a disease or condition from the 
DTCA.
Therefore, in terms of situated meaning, we cannot ignore the strong similarities 
which exist between the two discourses. Both patent and prescription DTCA tend to use 
language in a m otif that builds connections between potential common health conditions 
and the consumers. The main difference is that in the patent DTCA, like Lydia 
Pinkham’s Vegetable Compound and Peruna, just about any symptom could be included
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in the ads. Although, today the FDA keeps strict controls on the pharmaceutical 
companies which forces drug companies to be more specific in the listed indications, the 
prescription DTCA still evinces a desire to use fear as a way to make the ads relevant to 
readers.
In addition, both patent DTCA and prescription DTCA consistently structure the text 
o f ads towards a theme that implies a condition is degrading the quality o f consumers’ 
lives and only the advertised drugs can help. In that regard, very little has changed 
between the directives in Lydia Pinkham’s Vegetable Compound ads that “No other 
medicine has such a track record o f cures...” and “Refuse to buy any substitute” 
(Pinkham 1906) and Dr. Jarvik’s assertion in the Lipitor ads that any generic drug would 
not be acceptable. Both discourses also tend to use syllogisms to help normalize or 
medicalize the prototypical simulations the public uses to make decisions.
Finally, the text o f both discourses contains elements which make other options 
irrelevant even if they could be effective to a given condition. In the past, the connection 
between patient and physician was broken because patent DTCA had the freedom to 
eliminate the interaction. With FDA requirements as to wording, prescription DTCA 
does not have this same tfeedom, but chooses instead to break the connection to future 
decisions about generic drugs and lifestyle changes.
Overall, in terms of situated meaning, prescription DTCA appears to approach the 
building task o f connections in a way that does not clearly indicate a genuine desire to 
enact any other situated meaning than that o f advertising. To ensure we are giving the 
discourse a fair examination, however, we will look at the ads through one final building 
task -  that o f sign systems and knowledge -  in the next chapter.
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CHAPTER 4
SIGN SYSTEMS AND KNOWLEDGE 
Thus far, we have seen how the building blocks of a discourse like pharmaceutical 
advertising shape meaning through identity and connections. However, these elements 
are far from being the only means o f creating a context for a situation. In fact, authors 
must work continuously to reinforce the “reality” (Gee 11) which is their ultimate goal 
for a particular discourse. A corpus will exhibit these other means o f accomplishing a 
desired effect, or the “who” doing “what,” through many building tasks. Besides the 
tasks o f identity and connections that we discussed in earlier chapters, a discourse will 
also tend to use visual images and text which make specific sign systems and knowledge 
important to a situation in an effort to foreground particular elements (Gee 13).
This chapter explores our corpus of advertising for this building task of sign systems 
and knowledge, again applying Gee’s criteria for the task to the patent advertisements for 
Lydia Pinkham’s Vegetable Compound and Peruna and the prescription DTCA for 
Nexium and Lipitor. An analysis o f both discourses in this manner will give us another 
lens through which to view the similarities or differences between the two advertising 
formats. Ultimately, this study will determine if  enough differenee exists in situated 
meaning to support pharmaceutical company assertions that they not only sell medicines 
but also educate readers to shape them into well-informed patients.
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Once more, Gee offers us assistance in doing a discourse analysis through his 
research questions for each building task. For the purpose of sign systems and 
knowledge, our prompts for exploration include:
1) What sign systems are relevant (or irrelevant) in the situation (e.g. speech, 
writing, images, and gestures)? How are they made relevant (and irrelevant), and 
in what ways?
2) What systems of knowledge and ways of knowing are relevant (or irrelevant) 
in the situation? How are they made relevant (and irrelevant), and in what ways?
3) What social languages are relevant (or irrelevant) in the situation? How are 
they made relevant (and irrelevant), and in what ways? (112-113)
The term “sign systems” may seem abstract at first, but this concept simply represents 
the various communicative tools we have at our disposal with which to convey an idea to 
others. Gee, in fact, strongly emphasizes that language is only one o f many sign systems 
and that we tend to pull graphs, images, equations, and other non-language elements from 
our discursive toolbox in a way that helps us create situated meaning in a social 
interaction. More importantly, the way we structure and position these sign systems, and 
how we use them to make knowledge or belief claims, undeniably privileges -  or values 
-  one system over another (Gee 101).
More importantly, sign systems are the essential building blocks for the construction 
of various types of knowledge. Therefore, we can use certain sign systems, either alone 
or in combination, to privilege a specific form of knowledge in a discourse. Gee points 
out, for instance, that Native Americans, or “real Indians,” transmit their “cultural 
knowledge” through sign systems that are difficult for “non-Indians” to imitate (25). The 
gestures and speech patterns of “Indians” make a claim to cultural knowledge that closes 
a discourse to outsiders. Other forms of knowledge tend to have their own sign systems 
and are often privileged in pharmaceutical advertising.
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Social knowledge is the term this thesis will use for the common or ordinary 
knowledge that is transmitted on an affective level through interaction with others in a 
group. This social knowledge usually takes the form of “everyday language” (Gee 101) 
and is mediated through the experiences of those around us. Social knowledge is difficult 
to quantify because it often privileges human emotions over factual data and relies on the 
recipient’s receiving and responding to stimuli. For this reason, Bertrand Russell referred 
to this type o f knowledge as “knowledge by acquaintance” or “experient knowledge” 
because it is conveyed through direct awareness.. .of the thoughts, feelings and desires” 
(qtd in Hayner 423) of others. As this chapter will show, the testimonials in 
pharmaceutical advertising are particularly effective in constructing social knowledge 
because for the recipient “social knowledge amounts to some capacity for cheater- 
detection, and some information about the reliability o f different types of people” (Kusch
11). Therefore, social knowledge can be privileged if readers of an ad believe a 
spokesperson or image to be genuine.
In addition to social knowledge, pharmaceutical advertising often uses sign systems 
that privilege or make claims to scientific and judicial knowledge. These types of 
knowledge tend to be -  or at least appear to be -  more fact-based and positivist, although 
both usually take advantage o f rhetorical appeals to persuade an audience. Claims to 
scientific knowledge would depend on the presence of observable data while judicial 
knowledge would be privileged with the use o f rules and standards for right and wrong. 
As we will see in this chapter, however, scientific and judicial knowledge, when used in 
advertising with outsiders (e.g. average consumers), effectively closes the discourse just 
as “non-Indians” are excluded from “Indian” discourse.
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In order to further clarify the building task o f sign systems and knowledge, Gee 
returns once more to the example o f a business meeting that this thesis included in 
chapters 2 and 3. In the situated meaning of the business meeting, we said the person 
leading the meeting behaves and speaks in a particular way to gain recognition as the 
chair, thus the identity o f the chair is situated in the discourse o f the meeting. At the 
same time, the person leading the meeting would use specific language to make 
connections between what is said in the meeting to a time outside of the meeting. 
Furthermore, the meeting chairperson would also ensure that he/she uses a social 
language and gestures (sign systems) which privilege the business environment -  or 
corporate knowledge -  versus using sign systems which would be more appropriate for 
“everyday” conversation (Gee 101). For example, we would typically speak to peers and 
subordinates in a much more professional manner, so we would not use the same 
language, body movements, etc., in a business meeting that we would use when speaking 
to close friends. We ean also think o f sign systems as being the outcome of how well we 
understand the nuances o f our rhetorical purpose.
In our study of pharmaceutical advertising, we can find many types o f sign systems 
whieh imply a type o f knowledge, but this chapter will pay particular attention to the 
various non-language sign systems, such as images and ad design, in the discourse. In 
addition, the social languages used throughout the unregulated patent DTCA and today’s 
FDA-monitored preseription DTCA will equally inform our determination of drug 
marketing’s situated meaning. Ultimately, this chapter will show how these sign systems 
work together to make eertain types o f knowledge -  specifically social, scientific, and 
judicial -  relevant (or irrelevant) in the discourse. It is important to mention at this point
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that some of the elements which will be discussed in this chapter as communicative signs 
were also mentioned in the previous chapters as part o f building identity or connections. 
This versatility is to be expected and occurs because, as Gee often notes, the components 
o f a discourse usually function as multiple tasks within a single situation. So, a particular 
element of an ad, such as a photograph, can easily assist an author in building identity, 
connection, and, as we will see in this chapter, knowledge.
Images played a large role as a sign system in the patent advertising published prior 
to FDA regulation. As we saw in chapter 2, the images helped establish identity for the 
drug maker, but, in terms of communicative systems, they also served as instant- 
recognition symbols for anyone who saw the ads. From only a quick glance, a reader 
knew instantly which sectors of the population the drug maker was targeting. Lydia 
Pinkham’s Vegetable Compound ads, for example, usually featured the familiar face of 
the maker or a female who could be a sister of sorts to the reader. These images typically 
took up a large portion -  in some cases over half the advertising space -  of the ads, so it 
is evident that the Pinkham company saw these non-language sign systems as being equal 
in importance to the text in making a knowledge claim to potential customers. Since the 
drug was touted as being a wonder drug for “female weakness” (Pinkham, 1883), the 
images would certainly have captured the attention o f women readers. Moreover, the 
visual aspect added weight and reinforcement to the many testimonials in the language of 
the ads.
Not surprisingly. Dr. S. B. Hartman’s company also positioned images in prominent 
areas o f its Peruna ads to quickly convey the type o f people who took the drug and to 
support the claims made in the textual component. More importantly, though, the Peruna
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ads used graphies whieh demonstrated the eompany’s belief that a diverse portion of 
soeiety should be taking the medieation. Like the Pinkham ads, the Peruna ads 
eonsistently divided the allotted spaee equally between text and drawings, although the 
Peruna ads ineluded images of men, women, and entire families rather than foeusing on 
just one démographie. One ad, in partieular, used a smaller drawing of a nun inset on a 
much larger image of the orphanage to which she was assigned. The overall drawing 
easily took up over half o f the ad and effeetively made the elaim that major institutions, 
such as “St. Vincent’s Orphan Asylum” (Peruna, 1899) were buying and using Peruna. 
The layout (e.g. font type/size, borders, etc.) o f the ads is itself a sign system beeause it 
telegraphs the soeial knowledge that the authors want the audienee to have after reading 
the discourse. According to James Harvey Young, this aspect of the patent DTCA was 
always a premeditated faetor beeause “Distinetive type indueed a feeling o f 
familiarity.. .[just as] pietorial symbols served the same function” (167). In the case of 
Lydia Pinkham’s Vegetable Compound, the ads used repetitive lines printed in various 
fonts that appeared in random plaees within an ad and eontinued into other ads for the 
drug. For instanee, one ad in 1879 (see Figure 12) used signifieantly different font from 
that of the surrounding text to share the overall message o f the ad in a few seattered lines. 
This larger, bolder font loudly tells the reader that “MRS. LYDIA E. PINKHAM” is the 
maker and that the drug is for “Female Complaints” and is a “METHOD OF CURE” 
(Pinkham, 1879). Other Pinkham ads used bolding, underlining, or fnlly borders to 
eapture these same thoughts in a few key areas of the text, sueh as in Lydia Pinkham’s 
name or the allusion to female illnesses.
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Figure 12. Advertisement for Lydia Pinkham’s Vegetable Compound -  1879
The Peruna ads mirrored the layout used in other patent DTCA, like Pinkham’s, 
because the Hartman company used different font sizes and types to help distinguish the 
drug and the people taking it. Most often, the Peruna ads employed a bolded headline 
like “PERUNA PROTECTS THE FAMILY. Coughs and Colds. Grip and Catarrh” (see 
Figure 13) at the top o f the advertising space to encapsulate the most important 
information. This formatting was a way for the Hartman company to impart social 
know ledge because, i f  the consum ers w ere to read on ly  the aforem entioned text, they  
would still walk away with a coherent message about the patent medicine.
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Figure 13. Advertisement for Peruna -  1901
The patent drug makers used the imagery and layout o f the ads to appeal to the 
emotions o f consumers and to thus privilege social knowledge about medicine and 
illness. O f course, to fully develop a message, the non-language aspects o f the patent 
DTCA worked in combination with the social languages in the discourse. According to 
Gee, multiple social languages or voices in a discourse are common and have the 
potential to make a corpus “heteroglossic.. .[or] ‘double-voiced’” (37). We can see this 
mix of social languages in patent DTCA because it tended to be composed of two 
different voices. The first voice was the authoritative, pseudo-scientific language we 
might expect to hear from a patent drug company trying to work its way into the 
discourse o f the medical profession. The words o f the third-person narrators in the Lydia 
Pinkham Vegetable Compound and Peruna ads, for example, were authoritative because
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they set the tone that both eompanies knew what was best for not only siek eonsumers but 
also for physicians. Thus, the ads placed emphasis on seientifie knowledge in lines such 
as “For all Weaknesses o f the generative organs o f either sex, it is seeond to no remedy 
that has ever been before the public” (Pinkham, 1883) and “ ...a  certain, absolute eure for 
eatarrh is a publie good” (Peruna, 1899).
The words in the ads also typified the medical terminology which was probably 
intrinsic to insiders o f the medieal profession but often unfamiliar, yet persuasive, to the 
public. The ads for Lydia Pinkham’s Vegetable Compound, for example, often stated the 
drug was good for “Falling of the Uterus, Leucorrhoea, Bearing Down Feeling...” 
(Pinkham, 1879) without speeifically explaining the terms or the stated indieations. The 
ads for Peruna from 1885 to 1901 overwhelmingly favored the term “catarrh” (Peruna, 
1899) and used it for just about any eondition imaginable. In fact, in Dr. Flartman’s 
opinion catarrh could mean anything from appendieitis to mumps to female eomplaints to 
“whatever ails you” (Adams 13). The abundant use o f strange, medieal-sounding terms 
with no el ear definition -  but with the appearance o f seientifie knowledge -  was therefore 
one of the most criticized features o f patent medicine advertising. Samuel Hopkins 
Adams seathingly reprimanded the patent medieines or “subtle poisons” (32) for 
persistently using terms not readily known to the seientifically ignorant, yet hopeful, 
eonsumer.
The seeond voiee we hear in patent DTCA is that of the average person engaged in 
everyday social conversation. The drug makers relied heavily on testimonials to help 
them sell the patent medicines because the words o f people who could be perceived as a 
reader’s family or friend were extremely eonvineing. Therefore, the language the ads
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used to create this familiarity had to be simple and homespun. One ad for Lydia 
Pinkham’s Vegetable Compound, for instance, featured the testimonial o f a young 
woman who stated, “It was highly recommended to me by a friend. Now I feel like a 
different girl; no more aches and pains. I am praising it to every one” (Pinkham, 1896). 
Employing this same type of social language, a testimonial in an ad for Peruna declares,
“I feel like a different person already. A number o f my friends have used it, and they 
think it is a wonderful remedy” (Peruna, 1886).
The construction o f this social language, with its direct sentence structures and easy 
vocabulary, shows that the drug makers wanted the discourse to be conversational. As 
mentioned earlier, this type of language is a good way to transmit social knowledge 
because the participants feel as though they share experiences within a relationship. Of 
course, many authors (Adams; Young; Bok) have questioned whether the testimonials 
were really written by consumers or were fabrications o f the patent drug companies, but 
consumers seemed to react favorably in either case. In terms o f privileging a particular 
social language, patent DTCA divided the advertising space equally between the two 
different sign systems, so we can see that they did not necessarily privilege one above the 
other. Instead, the patent drug makers preferred to keep the two languages working in 
tandem to make an assertion to the reader.
An important point to note, however, is that the patent DTCA did not privilege 
scientific knowledge or value any language or information in the ads that was not directly 
related to the advertised drug. For example, no patent advertising ever mentioned the 
causes for a condition or the alternative choices available for alleviating an illness. 
Instead, the patent DTCA included text in every ad that directed readers to write to the
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drug maker for more information about healthcare issues rather than waste advertising 
space to any educational material. The Pinkham company, for instance, had its “Guide to 
Health” available for requestors while the Hartman company offered a booklet entitled 
“Ills o f Life.” These information pamphlets, however, often turned out be nothing more 
than additional advertising for the patent medications (Adams; Young).
As we saw earlier in this thesis, patent DTCA provides us with a good example o f a 
discourse whose primary situated meaning was the advertisement of a product to the 
public. In the building task o f sign systems and knowledge, the patent DTCA once again 
supported this “who doing what” o f advertising in a number of ways. The non-language 
sign systems -  the images and format -  facilitated the social knowledge about the drug 
that the patent medicine companies hoped to convey. The social languages, also key sign 
systems, in the text of the ads allowed the audience to hear both the voice of a 
knowledgeable “medical” professional and the familiar voice inherent in everyday 
interaction with friends. These sign systems were intensely focused on the product and 
combined to make knowledge claims about the patent medicines which would help 
increase overall sales o f the drug.
With our awareness of patent DTCA’s situated meaning, we can now analyze in 
comparison today’s prescription DTCA, also examining its use o f sign systems and 
knowledge as a building task. As in previous chapters, our focus will include similarities, 
but will ultimately search for any key differences the prescription DTCA have from the 
patent DTCA. Significant differences we find in the use of sign systems and knowledge 
would help support pharmaceutical company assertions that they are doing much more 
than advertising a drug.
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As a communicative tool, images have certainly retained their value to the discourse 
o f drug makers. In fact, the modem ads have access to techniques, like color 
photography and digitally generated graphics, that patent medicine manufacturers could 
only have imagined. Therefore, the visual aspects o f prescription DTCA today are eye­
catching with their tme-to-life representations of people and products. If we were to look 
solely at the images in the ads for Nexium, for example, we would always see the pill -  in 
its lifelike purple and gold form -  that the AstraZeneca company is featuring. The image 
o f the pill silently makes the claim that only this particular drug is going to help heal acid 
reflux, so the consumers need to know exactly what the pill looks like when they request 
it from their doctor.
The Nexium ads also use photographs o f everyday people who look healthy and 
happy, but, as we soon discover, are unaware of their problems. The people featured in 
the color photographs are fathers, teachers, grandfathers, etc., and all look toward the 
camera with smiles and robust demeanors. In one Nexium ad, for instance, a father is 
laughing with his children as they all play in a tree house together. At first glance, the 
reader gets the impression that this is a normal family doing everyday activities. But, the 
captions inset on the photos actually disprivilege the happy scenario in the photo with 
warnings about the impending illness that is ready to strike down the father. Even though 
the photographs take up over half o f the advertising space, the captions take precedence 
with statements such as “Knows they have homework. Knows they have chores. Knows 
their favorite hiding place. Doesn’t Know acid reflux may be damaging his esophagus” 
(Nexium, Sep 2006). Suddenly, what the readers initially thought they knew turns out to 
be incorrect.
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The ads for Lipitor use color photographs in ways that not only build social 
knowledge but also make vague claims to scientific knowledge in order to add prestige to 
the captions. At the top of every ad, the ubiquitous representative of Lipitor -  Dr. Robert 
Jarvik -  gazes calmly at the reader with a reassuring smile. He wears a white lab coat 
and a blue-plaid shirt whose colors exactly match the colors in Pfizer’s blue logo that 
appears at the bottom o f the ads. If we look closely at the image, we also see other 
people wearing white coats in the background. In fact. Dr. Jarvik and these other people 
appear to be standing in a laboratory of some kind (see Figure 14).
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Figure 14. Advertisement for Lipitor -  Dec 2007
Without even reading the text, the reader can quickly look at the photograph and 
conclude that this is a group of medical professionals engaged in scientific endeavors.
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This assumption can lead readers to believe the group will share reliable, scientific 
knowledge with them. The captions inset onto the photograph then use another type of 
non-language sign system -  numerical percentages -  to further support and privilege this 
idea. For example. Dr. Jarvik himself assures the reader that “Lipitor lowers bad 
cholesterol 39-60%...” (Lipitor, Dec 2007). Statistics such as these, although not fully 
explained in the ads, can be very persuasive to an audience which is uneducated about the 
medical studies.
Other non-language sign systems in the prescription DTCA are equally reminiscent of 
the patent DTCA because the ads depend on formatting to privilege a message and make 
a knowledge claim about the drugs. AstraZeneca is especially creative at doing this in its 
layout for the Nexium ads. All we have to do is look at the colors used in the design of 
the ads to see that they foreground a correlation to the “little purple pill” (Nexium, Jun 
2007). Every ad for Nexium uses a purple background to the textual fields of the ads. In 
addition, most o f these ads separate the textual element from the visual component with a 
small gold line. Each of the captions for the image at the top of the ads is also underlined 
in gold. In combination, these colors -  purple and gold -  call to mind the exact drug 
Pfizer is marketing in the situation. In effect, looking at the ad’s visual cues in their 
entirety is the same as looking at one of the Nexium pills.
Moreover, the Nexium ads echo a technique we saw in the patent DTCA for Lydia 
Pinkham’s Vegetable Compound by strategically placing bolded lines of text -  again in 
AstraZeneca’s trademark purple -  in random positions throughout the advertising space. 
These lines are in a larger font size than the surrounding text, so they quickly stand out to 
the reader. One Nexium ad (see Figure 15), in particular, demonstrates how scattering
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key lines o f text and using various non-language sign systems can effectively come 
together to build social knowledge in prescription DTCA. First, this ad’s entire 
background is a single, color photograph of a woman wearing a red scarf. The red scarf 
is carefully positioned in the image to represent the woman’s irritated esophagus. We 
soon leam this is true because a font -  in a different type from that of the rest o f the ad -  
is superimposed on the length o f the scarf claiming, “Behind this scarf acid could be 
burning the lining o f her esophagus” (Nexium, Jul 2006). To reinforce our knowledge as 
to how dangerous acid reflux can be, the scarf is knotted around the woman’s neck. As is 
the typical color scheme for Nexium ads, the woman is wearing a light purple shirt and is 
standing against a dark purple backdrop. The graphic o f the purple and gold Nexium 
capsule is positioned close to the woman’s heart.
Npiff'tnrt.
Figure 15. Advertisement for Nexium -  Jul 2006
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This Nexium ad then employs the technique o f formatting certain lines in a different
font type/size in a way that communicates a coherent message even if  readers were to
only read those lines. As shown in Figure 15, the resulting message from the scattered
lines in this particular ad is:
IT’S DIFFERENT FOR PEOPLE WITH ACID REFLUX DISEASE. Because 
beneath the heartburn, something more could be brewing. Acid reflux disease can 
damage your esophagus. NEXIUM heals the damage. Talk with your doctor 
about Nexium. FOR A FREE TRIAL OFFER, Visit PURPLEPILL.COM.... 
(Nexium, Jul 2006).
The ad does mention a medical condition, but the focus o f these carefully placed lines is 
directly on the prescription drug that AstraZeneca is advertising.
An example o f a Lipitor ad which effectively ties together several non-language sign 
systems to build social and scientific knowledge is shown in Figure 16. The photograph 
and graphics o f this ad dominate over half o f  the advertising space. The photograph 
shows Dr. Jarvik in casual street clothes this time versus his usual white lab coat. The 
caption under the image privileges this apparel as it states Dr. Jarvik is “Inventor o f the 
Jarvik Artificial Heart and Lipitor User” (Lipitor, Nov 2007). Thus, the readers now 
know that Dr. Jarvik is not only a medical professional but also one o f the audience 
members -  an insider who shares their social knowledge.
In the photograph. Dr. Jarvik stands in front o f a dark background in which we now 
see a much-larger, realistic scan o f a human skull and brain. Subtly, the image makes the 
claim that Dr. Jarvik also possesses scientific knowledge because he can discuss aspects 
o f the brain. To the side of the brain scan and Dr. Jarvik, the ad also privileges a 
numerical statistic stating, “ .. .Lipitor reduces risk o f stroke by 48%” (Lipitor 2007). 
Directly under the photograph, this Lipitor ad shows a blue field which coincides with the
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colors Pfizer uses for their logo. The familiar blue font is then carried over into the 
remaining textual component o f the ad for continuity. As with the Nexium ads, the 
Lipitor ads use these non-language sign systems to privilege the medication, and any 
stated symptoms of a health condition are usually re-routed back to the drug.
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Figure 16. Advertisement for Lipitor -  Nov 2007
Short quizzes, another innovative method for communication, also appear in 
prescription DTCA to help build a perception o f scientific knowledge about a drug. 
Nexium ads, for example, sometimes use a three-question, true/false quiz for readers to 
answer. The questions include such statements as “If I have heartburn, I shouldn’t worry 
about it” (Nexium, Sep 2006) and are portrayed as attempts to dispel myths about acid 
reflux. O f eourse, the answer to the question previously mentioned is “False” (Nexium,
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Sep 2006), so the non-language sign systems again bring the reader’s attention right baek 
to the advertised drug. The quizzes in preseription DTCA are unique elements that invite 
eonsumers to read themselves into the ads as they answer the questions.
The language sign systems in preseription DTCA also have a great deal in eommon 
with the patent DTCA beeause we again hear multiple voiees in the diseourse just as we 
did in the historieal ads. Whereas the patent DTCA showed two distinet soeial languages 
working together, however, the preseription DTCA shows a tendeney to use three 
languages which ironically do not work as well in combination. First, prescription 
DTCA mirrors patent DTCA in that it often speaks to the readers in the soeial language 
o f everyday conversation. The ads for Nexium, for example, often use humor in the 
short, declarative sentences which form the captions for the visual elements. One ad 
demonstrates this when it alludes to an old, familiar joke as it states, “Knows no dog has 
ever eaten any homework” (Nexium, Jun 2007). Other preseription DTCA continues to 
use testimonials in the form of well-known spokespersons, like Lipitor’s Dr. Jarvik, who 
talk to the audience in simple-to-understand language and appear to take the readers into 
their confidence. These conversations with the readers are not very different from the 
interactions we usually have with friends or family.
Next, preseription DTCA uses the authoritative voiee usually reserved for the 
seientifie language of medieal professionals in a way that is similar to the language in 
patent DTCA, although the tone in today’s advertising appears to be more tentative in its 
approach at times. Just as a physician would first diagnose a problem and then prescribe 
treatment for it, the preseription DTCA tells the readers what their health problem 
probably is and what the treatment -  the advertised drug -  should be. The Nexium ads.
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for instance, begin with bolded headlines such as “Even if you’re treating your heartburn, 
you may still have damage” (Nexium, Jun 2007) and “This condition may affect 1 in 3 
people with acid reflux disease, and if  left untreated, could get worse” (Nexium, Jan 
2007). In participating in the language of medical experts, prescription DTCA does 
provide an explanation, o f sorts, for the indicated health condition, but the clarification 
normally comes in the form of parenthetical definitions which do not fully expound on 
the causes or symptoms.
Instead, the ads tend to make social knowledge more relevant than scientific 
knowledge because they give one or two distinguishing features o f the stated health 
concern and then return quickly to the brand name of the drug. Nexium ads, for instance, 
prefer to state, “If you suffer from acid reflux disease -  persistent heartburn 2 or more 
days a week, despite treatment and diet change -  you could have serious damage to your 
esophagus and not know it” (Nexium, Jan 2007). In this statement, acid reflux is defined 
in a parenthetical manner as stubborn heartburn even though many other symptoms are 
typically present if  a person genuinely has acid reflux. Pfizer’s ads for Lipitor use the 
same method o f definition in the discourse, but their primary emphasis is on defining the 
drug rather than the health issue. For example, Lipitor ads usually begin with the line 
“LIPITOR is a prescription drug” (Lipitor, Nov 2007) and proceed to list what Lipitor’s 
distinguishing features are. The ads tell readers that “It [Lipitor] is used in patients with 
type 2 diabetes, and at least one other risk factor for heart disease...” (Lipitor, Dec 2007), 
but do not explain what the term “heart disease” can encompass.
In addition, the ads continue the vague scientific discussion with a remedy for the 
health problem. Naturally, pharmaceutical companies want to sell their products, so the
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prescription DTCA offers a cure in the form of the advertised drugs. Nexium ads make a 
claim to scientific knowledge when they state the drug “not only provides 24-hour relief 
from heartburn” but also “can heal even the most severe erosions in the esophagus caused 
by aeid reflux” (Nexium, Jan 2007). At the same time, this knowledge is made less 
relevant when the language in the ads significantly modulates the phrasing with 
qualifying words, sueh as “if,” “may,” and “could” that conflict with the confident timbre 
we would expect o f a licensed medical professional. The ads also include the reminder 
that “only a doctor can determine if  you have this condition” (Nexium, Sep 2006), but 
this statement is a requirement o f the FDA and establishes the third voice -  that of legal 
professionals -  in prescription DTCA.
Pharmaceutical companies predominately use language to build judicial knowledge in 
their DTCA in a way that was unheard o f in historical, patent medicine advertising. 
Ironically, this third voice of prescription DTCA has evolved through FDA laws 
pertaining to “product-claim” ads. These ads allow the drug manufacturer to focus on 
specific prescription medications and the situations which would indicate the need for the 
drugs, but in presenting a drug to the public, the drug company must follow a set o f rules 
the FDA outlines. For example, a produet-elaim ad “must present a ‘fair balance’ o f 
benefit and risk information” and “if  they are in print, contain a ‘brief summary’ o f a 
drug’s side effects, indications and effectiveness” (NIHCM 14). Interestingly, these FDA 
rules inadvertently set up a unique, and often eonflieting, combination of marketing and 
legal genres for the prescription DTCA.
In fact, the juxtaposition of soeial languages in produet-elaim DTCA establishes a 
context in which the consumers receive information in a discordant mixture.
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Furthermore, when the building task of “sign systems and knowledge” is used to analyze
the ads, an indication o f how “various ways o f knowing” (Gee 112) can affect meaning
and value becomes evident. For example, consumers reading the front page o f a Nexium
or Lipitor ad will hear the voice which tells them that the advertised drug is safe and
indicated for the stated condition. However, since these product-claim ads are allowed to
mention both a medicine and a medical condition, AstraZeneca and Pfizer must detail all
of the FDA-mandated information, such as safety considerations and side effects, on the
reverse or opposite page. This cautionary information develops from legal precedents in
most cases, so the language sounds legislative in nature, is often difficult for the
layperson to decipher, and ultimately seeks to avoid future lawsuits. The language of
lawyers comes through in the densely packed text on the reverse side of Nexium ads, for
instance, in a sea o f terms that would understandably be impossible for average
consumers to decipher:
Symptomatic response to therapy with NEXIUM does not preclude the presence 
of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric 
corpus biopsies from patients treated long-term with omeprazole, o f which 
NEXIUM is an enantiomer. ..Esomeprazole is extensively metabolized in the liver 
by CYP2C19 and CYP3A4. In vitro and in vivo studies have shown that 
esomeprazole is not likely to inhibit CYPs, 1A2, 2A6, 2C9, 2D6, 2E1, AND 
3A4.... (Nexium, Sep 2006)
Thus, the reverse side o f the ad issues a complex warning of serious effects of the drug
while the front side of the ad promotes the drug as having “a low occurrence o f side
effects, which may include headache, diarrhea, and abdominal pain” (Nexium, Sep 2006).
Admittedly, the Lipitor ads do a slightly better job than the Nexium ads of 
interpreting the legal language for consumers and speaking in a more natural voice, but 
the overall result is identical. For example, the front side o f Lipitor ads tries to allay the
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fears o f potential users with the statement “If you take LIPITOR, tell your doctor if  you 
feel any new muscle pain or weakness. This eould be a sign of rare but serious muscle 
side effects” (Lipitor, Dec 2007). This claim that negative effeets hardly ever happen is 
encouraging to readers, but the reverse side of the ad complicates the knowledge by 
stating the “musele problems.. .can lead to kidney problems, ineluding kidney 
failure.. .Your ehanee for musele problems is higher if  you take eertain other medieines 
with LIPITOR” (Lipitor, Dee 2007). Suddenly, the musele problems take on a greater 
significance for consumers, and the ad never explains what other medications might 
cause these life-threatening issues in combination with the advertised drug.
The two different intentions in the languages -  encouraging versus warning -  have
separate and distinet situated meanings o f their own and thus affect the knowledge the
eonsumer derives from the ads. Gee points this out in his own analysis of two soeial
languages he observed on the label of an aspirin bottle:
The first speaks with a lawyerly voiee {who) responding to specific potential legal 
problems and court eases {what)\ the seeond speaks with the official voiee o f a 
earing, but authoritatively knowledgeable company {who) trying to protect and 
advise people, especially women and children, while still stressing that aspirin is 
not particularly special or dangerous compared with drugs in general {what). Of 
eourse, the seeond who-doing-what sits in some tension with the first. (37)
This eonfiiet between the languages — and the forms of knowledge -  contributes to 
the reason why very few eonsumers actually take the time to fully read the text on the 
reverse side o f the preseription DTCA. When faced with a choice between the soeial 
knowledge that a drug offers hope for a better quality of life and the judicial knowledge 
enacted through confusing language that acts as a disclaimer and strives to ward off legal 
problems, readers naturally gravitate to the former mode of communication. Studies have 
indicated that the complex wording of the legal jargon deters eonsumers from reading the
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information in most cases (Murray et al, 513). The prescription DTCA appears to 
anticipate this action and relies on repeated imperatives to see a doctor for more 
information or training.
Therefore, prescription DTCA constantly repeats that consumers should see their 
doctors for an explanation o f the language in the ads or -  as patent DTCA once did -  asks 
consumers to send away for a free pamphlet from the pharmaceutical company. This 
method o f building knowledge works against the idea that the companies might use the 
ads to provide education about a disease or condition. In fact, both the non-language and 
language sign systems in prescription DTCA indicate that only the advertised drug is 
truly privileged in the discourse, and even most exhortations to talk to a doctor are in the 
context o f asking for the drug. In their defense, pharmaceutical companies assert they 
refer readers to a physician for advice in order to better educate the public, but as David 
R. Hall found when he analyzed medical leaflets, “frequent exhortations to ‘see your 
doctor’ actually militates against the effectiveness and usefulness o f these consumer 
product” documents (273).
Overall, in comparing prescription DTCA’s situated meaning to that o f patent DTCA 
for the building task of sign systems and knowledge, the communicative signs of 
prescription DTCA do not exhibit strong differences which would validate the 
pharmaceutical companies’ assertions that the product-claim ads are educational material 
for the public. In both patent and prescription DTCA, the images, statistics, and soeial 
languages on the front side o f the ads work together to build prestige for and social 
knowledge of the advertised drug. At the same time, the language on the reverse side o f 
today’s ads -  albeit a mandate from the FDA -  privileges a voice that works in opposition
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to the other sign systems. In fact, one has to wonder if  the pharmaceutical company 
would even include this information if  it were not directed in FDA guidelines because the 
density of the material detracts from the desired goal o f marketing a product.
Moreover, when readers want to gain actual scientific knowledge about a disease or 
condition, the tiny print at the bottom of the ad does not offer much assistance. Instead, 
physicians are expected to know everything about all prescription drugs because they 
serve under the learned intermediary doctrine (LID) which “places the responsibility 
solely on healthcare professionals to ensure that patient-consumers are adequately 
warned, and thereby shields manufacturers from failure-to-wam suits” (Ronald, 288). 
Thus, the effect the sign systems have on the relationship between doctors and patients 
and their ways o f knowing about a drug is exactly what has created considerable 
controversy today.
As this thesis has explained in previous chapters, however, we must pull together the 
various building tasks that function within a discourse in a comprehensive manner in 
order to validate an analysis of situated meaning. The next chapter will accomplish that 
goal by revisiting the building tasks o f identity, connection, and sign systems and 
knowledge as well as reach a conclusion about the nature o f “who doing what” in 
pharmaceutical DTCA.
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CHAPTER 5
MAKING A VALID CONCLUSION
Over time, people interacting within a community or particular activity will establish
a way of speaking and writing which has special meaning within the context of the group.
Any new members to the group will either have to adopt these same ways of
communicating or risk being ostracized from the others. This common way of speaking
or writing within the group helps members form attachments and gain acceptance as
insiders with the others. Therefore, the discourse used within the group will demonstrate
a specific situated meaning or what Gee calls the “who doing what” (22-23) to convey
ideas and messages. Gee further explains that:
The key to Discourses is “recognition.” If you put language, action, interaction, 
values, beliefs, symbols, objects, tools, and places together in such a way that 
others recognize you as a particular type o f who (identity) engaged in a particular 
type of what (activity), here-and-now, then you have pulled off a Discourse (and 
thereby continued it through history, if  only for a while longer). (27)
It follows, then, that when the insiders of a community want to make changes to their
situated meaning, the discourse again should evince signifieant markers that show this
desire for change to be true. Furthermore, the only way to genuinely know if a situated
m eaning has changed is to carefully analyze past exam ples o f  the d iscourse in
comparison with new artifacts, examining both for the ways in which they build meaning.
This comparison is necessary because “sometimes what we build is quite similar to what
we have built before; sometimes it is not” (Gee 10).
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The specific activity o f advertising medications to the public is, and has been for a 
long while now, a subject o f much debate in our society. As we saw in chapter 1, the 
fight to regulate what drug makers can say to the public started in 1905 with Samuel 
Hopkins Adams’s Great American Fraud articles and continues today. Critics, past and 
present, of DTCA argue that the discourse is merely the language of marketers whose 
only concern is selling a product. The pharmaceutical companies today, however, assert 
that the new prescription DTCA has elements which not only talk about a brand-name 
drug they wish to sell but also are intrinsically educational about diseases and conditions.
Like it or not, consumers and their physicians have always been the targets of 
medicine advertising and therefore have the ultimate responsibility in deciding which 
advertised drugs are warranted. As early as 1800, Young points out that an editor stated 
about patent DTCA, “The vendors of patent medicines.. .in the U.S. are fattening on the 
weaknesses and folly of a deluded public” (32). The advertising continues to this day, so 
the constant barrage of multi-media print and television advertising forces consumers to 
make judgments about the content and claims. The consumer, unfortunately, is thus 
under considerable pressure to distinguish between selling technique and factual 
information. Therefore, the audience for drug marketing would benefit greatly from a 
close reading o f the ads to better understand the intentions exhibited in the discourse.
The challenge for this thesis was to determine if  the pharmaceutical companies’ 
claims -  that the situated meaning in their advertising was different from that o f earlier 
drug advertising -  is accurate. To accomplish this goal, the study had to include 
examples of drug advertising from the past because older artifacts of a corpus are 
essential in comparing the discourse across time. Since the non-regulated patent DTCA
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theoretically falls within the same discourse community as the prescription DTCA, this 
study went all the way back to the advertising that Adams was so contemptuous of in his 
1905 critiques. This study thus selected two samples -  Lydia Pinkham’s Vegetable 
Compound and Peruna -  from the many artifacts o f patent DTCA available for use in this 
analysis because both patent drugs sold extremely well and were mentioned by name in 
Adams’s articles. These patent ads were then placed alongside two of today’s ads for 
prescription medications -  Nexium and Lipitor -  using Gee’s theory for examining 
situated meaning as the methodology for the comparison. The next concern o f this thesis 
was to ensure that the method of analysis was valid. Once again. Gee’s theory of 
discourse analysis provides criteria which assists us in determing validity.
In fact. Gee discusses two criteria -  coverage and convergence -  which, if  shown to 
exist in an analysis, can ensure the determination o f whether a discourse’s situated 
meaning is valid. Gee explains that “the validity o f  the analysis will reside in how the 
ideas we can generate [from one set of artifacts] help to illuminate other data (coverage), 
data that we hope will lead us to similar constructions (convergence)” (Gee 154). In 
other words, unless we have these standards by which to judge a final determination, we 
cannot expect any analysis to be convincing. Therefore, this chapter will explain how 
this study o f patent and prescription DTCA met both the criteria o f coverage and 
convergence in its effort to do a sound analysis. In addition, this chapter will make a 
final assertion about the nature of prescription DTCA’s situated meaning and offer 
recommendations to pharmaeeutieal eompanies in regard to their advertising.
Coverage, as Gee defines it, is the premise that “the analysis is more valid the more it 
can be applied to related sorts o f data. This includes being able to make sense o f what
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has come before and after the situation being analyzed...” (114). With that idea in mind, 
this study began its analysis of pharmaceutical advertising with a search for artifacts that 
were representative o f a corpus of patent and prescription DTCA. The amount of 
material available for historical and current drug advertising is overwhelming to say the 
least. With the set o f artifacts in hand, this thesis then examined the patent DTCA that 
predated today’s prescription drug advertising for indications o f the construction tools or 
building tasks that Gee provides in his theory o f discourse analysis. It quickly became 
apparent that any of Gee’s building tasks would have been appropriate for looking at the 
pharmaceutical advertising, but this study focused on identity, connections, and sign 
systems and knowledge because these methods for creating reality within the situated 
meaning were most evident.
The study then employed the same analysis for the building tasks o f identity, 
connections, and sign systems and knowledge to make a fair and consistent analysis of 
the prescription DTCA. Although other building tasks were clearly present in 
prescription DTCA, the study did not deviate from those elements used to evaluate patent 
DTCA. In this way, the thesis achieved the validity marker, as Gee defines it, of 
coverage and could progress to the issue of convergence.
The premise that a corpus will tend to have the same situated meaning -  who doing 
what -  the more the building tasks meld within and between artifacts was an extremely 
important factor for this study’s overall purpose. According to Gee, “a discourse analysis 
is more, rather than less, valid (i.e., ‘trustworthy’), the more the answers to the [questions 
outlined in his building tasks] converge in the way they support the analysis or, put the 
matter the other way round, the more the analysis offers compatible and convincing
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answers to many or all o f them” (113). Therefore, this thesis predicted that if  the analysis 
did not result in significant convergence of the building tasks in patent and prescription 
DTCA, the likelihood that their situated meaning was the same would be very small.
This outcome would then have supported pharmaceutical companies in their argument 
that prescription DTCA has an educational role about diseases and conditions and is not 
simply a marketing tool for the drugs. On the other hand, if  there were considerable, or 
possibly absolute, convergence between patent and prescription DTCA on the building 
tasks, the prescription DTCA’s situated meaning would be identical to historical 
examples of medicine advertising and would not lend credence to the idea that 
prescription DTCA is different from earlier drug advertising.
Considering the criteria o f convergence, we can see that the building tasks of identity, 
connections, and sign systems and knowledge in patent DTCA came together in a number 
of ways in the visual and textual components o f the ads to highlight a company selling a 
product. First, the visual component functioned to build both identity and sign systems 
and knowledge. In previous chapters, we discussed how the Pinkham and Hartman 
companies carefully crafted the identity they wanted to be perceived as having in the 
discussion of healthcare through the illustrations o f people who were safely and happily 
taking Lydia Pinkham’s Vegetable Compound and Peruna on a daily basis. The Pinkham 
company centered its imagery on women, especially on Lydia Pinkham herself, because 
the medication was supposed to be good for “female weaknesses” (Pinkham, 1883). The 
illustrations o f the caring, motherly figure o f Lydia Pinkham helped solidify her authority 
to speak to other women on the subject of their medical needs. As times changed for 
women, the Pinkham company also became adept at creating new images of women, or
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“working girls” (Pinkham, 1896), in the workplace to maintain the drug maker’s role of 
advisor to women. As for the imagery in the Peruna ads, the Hartman company went 
after practically everyone in the general public, as the DTCA clearly demonstrated with 
ever-changing drawings o f men, women, nuns, congressmen, and entire families. The 
Hartman company clearly wanted the position o f medical expert and authority for all 
consumers. Both patent drug makers, therefore, visually conveyed the image they 
wanted to have with society.
But, as previously mentioned, identity for the companies was only one part of the 
value o f visual components because they worked equally well for the building task of 
sign systems and knowledge. The illustrations o f the female customers in the ads for 
Lydia Pinkham’s Vegetable Compound, as non-language sign systems, communicated to 
women who might not be using the drug that they too could trust the medication to be 
effective. Considerable advertising space -  up to half the page in most cases -  was 
devoted to the drawings o f average women said to be taking the drug, so the Pinkham 
company obviously realized a way to fully engross a female reader who might otherwise 
bypass the ads. In keeping with its identity, the Hartman company’s imagery in the 
Peruna ads made the claim to consumers that a wide variety o f people believed in the 
efficacy o f the medication. After all, one ad even subtly indicated that an entire 
orphanage was using a steady supply (Peruna, 1899).
The layout o f the ads was another non-language sign system that greatly affected 
awareness o f the patent drugs (identity) and easily merged with the task o f building 
connections. In particular, randomly scattered lines of text -  in a distinctively different 
font type/size than that o f surrounding lines -  ran throughout the layout o f the ads for
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Lydia Pinkham’s Vegetable Compound and formed a coherent message to readers when 
the lines were joined together. This sign system not only made the knowledge claim that 
the drug was a “METHOD OF CURE” (Pinkham, 1879) but also helped women change 
their ideas o f what should be considered normal or abnormal, one o f the common motifs 
in patent DTCA. As we saw in chapter 3, the treatment o f common symptoms as a 
problematic condition influenced consumers’ “prototypical simulations” (Gee 95-96) for 
illness. In this case, simply being female somehow connoted a weak character that must 
be treated with a chemical remedy. The Hartman company’s imagery capitalized on this 
theme too, but they exhibited a layout that privileged a larger audience for its product in 
an effort to also help a diverse population make the connection that certain illnesses, like 
the ubiquitous “catarrah” (Peruna, 1899), were universal to all members of society -  
another motif o f patent DTCA -  and must be cured with multiple bottles of Peruna.
The textual component of the patent DTCA complemented the messages of the visual 
element and demonstrated convergence in its overwhelming compatibility in all three 
building tasks o f identity, connections, and sign systems and knowledge. In terms of 
identity, we saw how the Pinkham company avoided direct “I” messages that might 
divert attention away from the manufacturer’s authority in discussions o f the drug. Only 
the testimonials, for example, for Lydia Pinkham’s Vegetable Compound and Peruna 
directly addressed the readers; otherwise the ads were narrated in a third-person, 
authoritative voice. This detached tone allowed the patent drug makers to escape some 
accountability and preserve the perception that the patent drug makers were every bit as 
professional about medicine as the regular physicians.
The text o f patent DTCA then continued the separation from medical doctors as it
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tried to break connections and assume multiple social languages to effect knowledge. For 
example, we discovered that Peruna ads were very straightforward in their attempts to 
make physicians irrelevant with persistent assertions that nothing but the drug was 
effective. This was a common theme in patent DTCA as “throughout history [promoters] 
have used a monistic theory with a one-shot therapy, and the panacea is the medicine 
advertised” (Young 170). Testimonials such as, “I did not call the doctor, but used your 
medicine” (Peruna, 1899), showed readers they could save themselves the trouble of 
visiting a physician. The duality o f the language sign systems reinforced this premise as 
the authoritative, “scientific” voice in the ads talked about symptoms in vague terms -  
like the “bearing down feeling” (Pinkham, 1879) that all women were reportedly 
suffering from -  and collaborated with the everyday conversational voice o f eager users 
of the drugs.
Without question, the building tasks o f identity, connections, and sign systems and 
knowledge that we observed in patent DTCA converged within the discourse to depict a 
patent drug maker (who) focusing all o f its energy and advertising space to concentrate 
on a product it was selling to the public (what). In fact, the patent drug makers did not 
typically claim to be doing otherwise, and this study found no evidence that the patent 
DTCA ever included much material of a truly educational nature. Thus, the entire 
situated meaning o f the marketing was to sell a medication and keep consumers from 
going to the patent drug makers’ biggest competitor -  regular doctors who would most 
likely dissuade patients from taking the advertised drugs.
Once this study had clarified the situated meaning of “what came before” (Gee 114) 
the current prescription DTCA, we could now apply the same criteria, or coverage, to
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today’s drug advertising to identity where, if  at all, convergence might take place. In the 
same building tasks o f identity, connections, and sign systems and knowledge, our 
analysis found that almost every point already mentioned for patent DTCA is to some 
extent evident in and compatible with the current prescription drug advertising.
Prescription DTCA’s visual component, for example, is used in much the same way 
as it was in patent DTCA to build identity and make claims through non-language sign 
systems, but this study shows it has more potential to capture attention due to advances in 
print media and a change in approach to the public. As we saw in previous examples, the 
images still take up at least half of the advertising space but are now published in glossy, 
color photographs that feature people who appear to be healthy. The accompanying 
captions, however, simultaneously gamer authority for the pharmaceutical company in 
the discourse and make a statement about who should be taking the drag. Unlike patent 
DTCA, prescription DTCA tends to spotlight people who are not yet taking the drag and 
address readers directly -  making frequent use o f “I” statements -  to draw the public into 
making a connection between their own health and that of the person in the photograph. 
Thus, the current advertising has a more personal effect on its audience than the patent 
DTCA once did.
In doing so, the pharmaceutical companies assert their authoritative position by 
telling readers that the people in the photographs don’t know how sick they really are. 
Ads for Lipitor have emphasized this expert role even further by insisting on including 
Dr. Robert Jarvik in every ad as its official, credible spokesperson and superimposing his 
image against a laboratory-like setting in the background to make a statement about the 
trustworthiness of the drug. This use of a personal spokesperson goes back to patent
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DTCA and works because “the perfect testimonial.. .must have the appearance o f truth 
and must he acceptable to those who, from lack of special knowledge, are unable to 
recognize any fallacy that may be present” (Holbrook 231).
The versatility o f prescription DTCA’s non-language sign systems when moving 
between the building tasks shows convergence in its efforts to keep the readers’ focus on 
the advertised drug. This premise is especially evident in the formatting o f the ads. The 
ads for Nexium, for example, usually display a prominent graphic of the “little purple 
pill” (Nexium, Jul 2006) near the top of the ad to clearly identify the drug consumers 
should request from their doctor. In addition, every ad uses the purple and gold 
background that acts as a visual reminder o f the pill itself. These non-language sign 
systems not only privilege the medication but also help build relevance (connections) in 
the readers’ minds for the drug and its brand name. Like the historical patent ads for 
Lydia Pinkham’s Vegetable Compound, the current Nexium ads have a proclivity for 
randomly scattering lines of text in a distinctive font to quickly convey a message about 
the drug when the lines are combined. Furthermore, the ads for Lipitor employ 
formatting -  special blue font that corresponds to the Pfizer logo -  that connects the drug 
to the company in the discourse and serves as a visual brand-name reminder to 
consumers.
In fact, prescription DTCA probably has a greater ability to build identity with 
consumers than did the patent DTCA since pharmaceutical companies now have a special 
avenue through reminder ads. As we discussed in chapter 2, the FDA’s alignment o f ads 
into three separate categories -  reminder, help-seeking, and product-claim -  has had the 
side effect o f allowing pharmaceutical companies to get their brand names out into the
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public to assume a role and make connections without having to worry about discussing 
the health effects or risks o f any particular drug. The reminder ads are espeeially adept in 
building identity for a company and making connections since the ads, by law, eannot 
mention the conditions for which a drug is advertised. This requirement allows the 
pharmaceutical companies to foeus entirely on building a positive image as a 
manufacturer.
The visual elements definitely aehieve several goals in the situated meaning of 
advertising, but the textual component — in the same way it did for patent DTCA -  
ultimately brings together all of the building tasks o f identity, connections, and sign 
systems and knowledge to direct our interest to a drug. In addition to the “I” statements 
already mentioned in the discussion o f imagery, the prescription DTCA uses language to 
simultaneously show affinity with physicians yet retain authority over the medicine 
discussion. The dilemma for today’s pharmaceutieal companies is that -  unlike patent 
drug makers who eould separate themselves from regular physicians to avoid competition 
-  they must send consumers to doetors in order to sell the product. Since physicians must 
be involved in the process to prescribe the advertised drug, the pharmaceutieal companies 
must maintain rapport with the medical field. However, the language of the prescription 
DTCA is often authoritative even when referring to doctors. The ads for Lipitor, for 
example, consistently tell readers what doctors “should” be doing to effectively provide 
healthcare to patients. As one Lipitor ad remarks, “Your doctor should do blood tests to 
check your liver function before and during treatment...” (Lipitor, Dee 2007).
The textual elements also work in much the same way as patent DTCA once did to 
both make and break conneetions in the discourse. For instanee, the syllogistic
96
construction of the discourse assists in the “medicalization” (Amey & Rafalovich 50) of 
common symptoms, thus enabling consumers to see a condition as being abnormal and 
needing a remedy -  motifs we first saw in patent DTCA. Today, for example, we even 
see ads for Botox that establish the idea for consumers that wrinkles around a woman’s 
mouth or eyes signify an undesirable health condition that needs to be fixed.
Furthermore, prescription DTCA also relies on the frequent use o f modal words, like 
“could” or “may,” in the discourse to force a connection to certain conditions while 
deflecting hlame for any misdiagnosis that might occur.
Finally, the text in prescription DTCA often makes irrelevant other forms o f care, 
such as diet and exercise or generic, less expensive drugs that would he just as effective. 
Interestingly, a recent class-action lawsuit was formed against the makers o f the 
prescription drugs Zetia and Vytorin for this method o f breaking connections. The ads 
for Zetia and Vytorin have claimed for the last several years that their drugs were more 
effective than generic brands, but studies have shown this claim to be false. Ironically for 
Lipitor, one o f the ads analyzed in this thesis, the ads for Vytorin are notorious for their 
comparisons o f Vytorin to Lipitor in their assertions that Vytorin “lower[s] bad 
cholesterol more than Lipitor alone” (Vytorin, Dec 2007). At one time, this comparison 
might have demonstrated how well Pfizer, the maker of Lipitor, was accomplishing its 
manufacturing goal since a competitor was using Pfizer’s drug as a benchmark, hut now 
the legal action against the makers o f Vytorin, and its advertising comparison, begs the 
question about Lipitor’s effectiveness. As a result, the scrutiny o f Lipitor as “one of the 
most researched medicines” (Lipitor, Dec 2007) is sure to continue. In fact. Congress
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recently expressed iriterest in questioning Lipitor’s spokesperson, Dr. Robert Jarvik, 
about misleading statements and practices in the DTCA (Saul).
The connections which are broken or established in prescription DTCA are further 
reinforced by and compatible with the sign systems of multiple social languages. 
Prescription DTCA, for example, mirrors the patent DTCA in its use o f both authoritative 
and conversational social languages. Most o f the ads we examined for Nexium and 
Lipitor exhibited the tendency to first diagnose a condition from stated symptoms and 
then prescribe a remedy -  the advertised drug. In doing so, the ads included language 
that spoke to consumers as a friend or peer would. These two sign systems work well 
together, just as they did in patent DTCA, to build trust and highlight the advertised drug. 
FDA regulations, however, have influenced a third language in prescription DTCA that 
creates a fundamental problem for advertisers.
The text on the reverse side o f product-claim ads in many ways negates the efforts of 
the social languages on the traditional marketing side o f the ads. From a continuity 
standpoint, the risks and contraindications listed on the back o f the ads do not converge 
well with the building tasks previously discussed. On the surface, this lack of 
convergence with what came before in the discourse might appear to indicate that the 
pharmaceutical companies are correct in their assertions that they are interacting in a 
different situated meaning, but in fact, the pharmaceutical companies have this third 
language thrust upon them. Read closely, the FDA-mandated text actually works against 
the pharmaceutical companies’ claims that they are educating consumers about diseases 
or conditions.
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The tone on the front side o f the ads, for instance, helps build the companies’ identity 
with its direct, conversational address to readers, but the reverse side o f the ads abruptly 
breaks the cormection with prescriptive language in a third-person, judicial voice. The 
material does little to educate a consumer about illnesses because this part of the 
advertising is only required to contain usage information about the advertised drug, and 
pharmaceutical companies do not usually add any other information that is not mandated. 
Interestingly, Harvard Business School also found that the listing of negative side effects 
of a drug, especially in the DTCA for Lipitor, actually decreased patients’ compliance 
with a prescription drug regimen (Wosinska). Furthermore, consumers often do not take 
the time to read through the complex wording. Instead, patients remember a few key 
phrases they might gather from the front side o f the ads and depend on physicians to 
know all the benefits and risks o f every prescription drug on the market.
As a result, product-claim DTCA has essentially de-privileged the interaction that 
doctors used to have only with drug companies, and consumers are now invited into a 
three-way conversation they may not be adequately prepared to have. Before the FDA 
allowed DTCA, pharmaceutical companies could only advertise to physicians, so doctors 
were better able to monitor claims about medications. Now, however, consumers are 
seeing many advertisements before their physicians do, and regardless of the multiple 
forms of sign systems in any drug ad, the patient ultimately seeks wording that promises 
relief from an adverse condition. Doctors claim patients now come to them, motivated by 
the DTCA, with only a surface knowledge of a drug. This situation has caused many 
critics of DTCA to lobby for changes in the learned intermediary doctrine -  the legal 
framework that releases pharmaceutical companies from liability because courts ruled (in
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the 1960’s) that doctors were in the best position to warn patients of all medication 
dangers. The opponents o f DTCA state the learned intermediary doctrine should be 
changed to place more responsibility on the shoulders o f the pharmaceutical companies 
since the advertising bypasses the physician’s control (Ronald).
As it stands now, the superficial awareness o f a drug and the connections established 
to symptoms o f a medical condition in DTCA’s situated meaning make some patients 
feel they can enter into the medical discourse on equal terms with the other participants. 
Pharmaceutical companies may create their ads with the ideal audience in mind, 
intending to reach only people who understand they must rely on a physician’s training 
for medical advice, but doctors are seeing patients who feel they now have the requisite 
knowledge to debate the necessity o f a medicine. Unfortunately, mass marketing 
prescription medications is not the same as marketing other commercial products. The 
ideal audience on a general population level does not exist because every medical 
condition varies slightly from another. Thus, the risk of a patient’s misinterpretation of 
an ad or a medical illness is a very real factor.
O f course, pharmaceutical companies claim they subvert this danger by including the 
advice to see a doctor; however, the drug manufacturers cannot accurately claim that the 
ads’ persistent encouragement to “see your doctor” is altruistic on their part. Once again, 
these statements are FDA-mandated text that actually help the drug makers allay some 
responsibility -  under the learned intermediary doctrine -  for genuinely educating 
consumers. Even if  the FDA did not require the wording, this tactic might not be as 
effective as pharmaceutical companies might hope. First, relying on doctors to dissuade 
the patient from taking a non-indicated medicine means that physicians must use valuable
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time getting familiar with every new drug on the market and talking patients out of 
certain choices. Fearful o f losing patients who might feel a doctor visit was not 
satisfactory (i.e. the doctor did not prescribe the requested drug), many physicians admit 
they sometimes prescribe a medication simply because the patient wanted it, as long as 
the drug would not harm the patient (Murray et al, 515). Second, most patients again do 
not have the training necessary to understand the complex interplay of symptoms and 
often are not able to distinguish their health issues from those indicated in the ads.
Therefore, upon careful analysis that included Gee’s validity criteria of both coverage 
and convergence, this thesis has determined that, for all of its advances in technology and 
FDA control, prescription DTCA has not moved very far -  at least not significantly -  
from the situated meaning of patent DTCA. The pharmaceutical companies’ claims that 
they are using the DTCA to educate the consumers might be true to the extent that they 
are informing the readers about a drug on the market. But, the claim that they are 
providing education about diseases and conditions is not well supported in the analysis of 
their discourse. In fact, many of the elements o f the ads make it difficult to find 
significant information about the causes of or preventative measures for health conditions 
and diseases. Rather the entire focus o f prescription DTCA, as it was for patent DTCA, 
is promotion of the advertised drug and mitigation of competition.
In today’s society, there is nothing wrong with advertising medications as a 
marketing tool; however, if  pharmaceutical companies want to show they are sincere in 
their efforts to educate consumers about diseases or conditions, they must demonstrate 
this desire in the DTCA. A recommendation this study would make to them would be to 
structure the discourse in a way that equally privileges information about medical
lOI
illnesses and treatments versus spending so much time on a particular drug. As we saw, 
pharmaceutical companies today already have a very effective way to capture readers’ 
attention as they build identity through reminder and help-seeking ads, so they could 
easily use that momentum to make information about lifestyle choices and alternative 
care more relevant in the images and text. In addition, the reverse side o f product claim 
ads, while it must contain side effects and risks o f a drug, could easily be transformed 
through a better balance of discussion for both drug and illness while using a social 
language which is more easily accessible to the audience.
While pharmaceutical companies might aspire to educate in DTCA, they are 
ultimately in business to make a profit. Therefore, consumers must look critically at 
prescription DTCA to determine the best course o f action to take for their health 
concerns. As Dr. Marcia Angell, editor o f the New England Journal o f Medicine 
asserted, “ ...that’s not their [pharmaceutical companies] business, education. Drug 
companies are not in the education business. Medical schools and teaching hospitals are. 
It’s like expecting beer companies to educate people about alcoholism. It is not what 
they do.” So, even with FDA controls in place and further studies in progress, 
pharmaceutical advertising has the potential to be misleading, or at the very least 
confusing, for readers. Furthermore, through the comparison in this study, we can see 
that today’s prescription DTCA has not significantly distanced its imagery and text -  and 
consequently its situated meaning — from the who doing what o f patent DTCA (see 
Figure 17).
As consumers, we should remember that as early as the Renaissance, Galen said there 
were three factors which could do much to build a patient’s confidence in physic: “a
1 0 2
strong personality in whom the individual has faith;” “an environment rieh in symbols;” 
and “suggestion” in a eourse o f treatment (qtd in Harley 431), so we must be eautious 
when reading ourselves into the discourse o f pharmaceutical advertising. As 
demonstrated in this thesis. Gee’s building tasks o f identity, conneetions, and sign 
systems and knowledge can help illustrate the methods drug companies use to establish 
an image with the public, make certain information relevant or not, and manipulate the 
sign systems o f medical discourse to influence patients’ decisions to request a drug from 
their doctors. Patient education through advertising, as espoused by pharmaceutical 
companies, eould be beneficial for patient and doctor alike, but true knowledge should be 
an end result.
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